Document:

EX-4.17

 Exhibit 4.17 

Certain confidential information contained in this document, marked by [***], has been omitted because such information is both not material and is the
type that Gracell Biotechnologies Inc. Company customarily and actually treats that as private or confidential. 
 EXCLUSIVE
LICENSE AGREEMENT 
 THIS AGREEMENT is made and entered into on May 11, 2021 (hereinafter the “Effective Date”) by and
between FutureGen Biopharmaceutical Co., Ltd. a PRC corporation, whose address is 201, 2/F, Building No.1, #16 Baoshen South Street, Daxing District, Beijing (hereinafter “FUTUREGEN”) and Gracell Biotechnologies (HK) Limited, a Hong
Kong company, whose business address is Building 3, 418 Guilin Road, Xuhui District, Shanghai, China 200233 (hereinafter “GRACELL”). FUTUREGEN and GRACELL are sometimes hereinafter referred to individually as a
“Party” and collectively as the “Parties”. 
 WHEREAS, FUTUREGEN has unique expertise in the area
of antibody development and protein engineering. FUTUREGEN is in the process of prosecuting an international PCT patent with respect to full human claudin 18.2 antibodies (“CLDN18.2”) of which the PCT application number is
[***]. (the “Patent”); 
 WHEREAS, FUTUREGEN wishes to have the Patent commercialized to benefit the public
good in the Field (as defined below); 
 WHEREAS, FUTUREGEN is willing to grant an exclusive license to its rights in the Licensed
Technology (as defined below) to GRACELL in the Field and GRACELL desires to receive such an exclusive license to commercialize the Patent in and for the market of the Licensed Territory (as defined below) subject to the terms and conditions of this
Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises herein made and exchanged, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE 1 INCORPORATION
OF RECITALS AND DEFINITIONS 
 1.1. The foregoing recitals are hereby incorporated herein by reference and acknowledged as true and
correct. Unless specifically set forth to the contrary in this Agreement, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below. 

1.2. “Affiliate” shall mean with respect to either Party, any other corporation or business entity that directly, or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, the term “control” and, with correlative meanings, the terms “controlled by”
and “under common control with” mean direct or indirect ownership of more than fifty percent (50%) of the securities or other ownership interests representing the equity voting stock or general partnership or membership interest of such
entity or the power to direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise.. 

 1.3. “Alliance Manager” shall have the meaning ascribed to it in
Section 12.7. 
 1.4. “BLA” shall mean a Biologics License Application, as defined by the U.S. Food and Drug
Administration, or and any other equivalent biologics license application practices applicable in other Licensed Territory (including without limitation biologics license application within National Medical Products Administration in the PRC) as may
be amended from time to time, or any successor application having substantially the same function. 
 1.5. “Change of
Control” shall mean 
  

	 	(a)	 any consolidation, merger, combination, reorganization or other transaction in which the Party is not the
surviving entity other than a transaction, the principal purpose of which is to effect a change in domicile or the form of entity of the Party; 

  

	 	(b)	 the shares of stock of the Party constituting in excess of fifty percent (50%) of the voting power are
exchanged for or changed into other stock or securities, cash, and/or other property other than in the context of a financial transaction; or 

  

	 	(c)	 a sale or other disposition of all or substantially all of the assets of the Party, or the permitted assignment
of this Agreement pursuant to Section 17.6. 

 1.6. “CLDN18.2” shall have the meaning ascribed to it
in the introductory paragraph. 
 1.7. “Confidential Information” shall mean all information disclosed by one Party to the
other during the negotiation of or under this Agreement in any manner, whether orally, visually or tangible or intangible form, that relates to Licensed Technologies (as defined below), or this Agreement itself, unless such information is subject to
an exception described in Section 5.2. Confidential Information shall include, without limitation, the following, whether or not patentable: materials, know-how and data (whether technical or non-technical), trade secrets, inventions, methods and processes created or used in the performance or receipt of the services provided hereunder, unless otherwise mutually agreed to by the Parties. 

1.8. “Effective Date” is defined in the introductory paragraph of this Agreement. 

1.9. “Executive Officer” shall mean the Chief Executive Officer of a Party. 

1.10. “Field” shall mean engineered or modified immune cell therapies, including but without limitation T cell, NK cell and
Macrophage cell therapies. 
 1.11. “First Commercial Sale” shall mean (i) a Net Sale, as defined below, made after the
Licensed Technology has received regulatory approval for commercial sale, (ii) the sale is a for-profit sale, and (iii) a minimum of ten (10) different patients have been treated as a result of
such for-profit sales. For the avoidance of doubt, a legally permitted use of a Licensed Technology in a market where the Licensed Technology has not been approved for commercial sale, for purposes of
(i) treating patients in a single patient trial; or (ii) providing expanded access outside of a clinical trial to patients with serious or life-threatening conditions who do not meet the enrollment criteria for a clinical trial, whether
the result of a sale or not, shall not constitute and shall not be considered a First Commercial Sale. 

  
 Page 2 of 25 

 1.12. “FUTUREGEN Know-How” shall
mean all know-how, technology, trade secrets, Information, regulatory files and data which, as of the Effective Date and during the Term that is controlled by FUTUREGEN or any of its Affiliates is necessary or
useful for the research, development, manufacture, use, sale, distribution, importation, exportation or commercialization of the Licensed Technologies in the Field in and for the Licensed Territory. 

1.13. “Generic Product” shall mean, with respect to a particular region and a Product, any pharmaceutical product that
(a) contains the same active pharmaceutical ingredient (or one which is substantially the same or bioequivalent) as such Product and is the same or substantially the same as such Product in dosage, safety, effectiveness, strength, stability,
and quality, as well as in the way it is taken and should be used; (b) is approved by the Regulatory Authority in such region (i) in full or partial reliance on the Regulatory Approval for the Product in such region in the Licensed
Territory in the Field or (ii) under a generic pathway approval as a generic of the Product in such region in the Licensed Territory; and (c) is sold in such region by a third party that is not a Sublicensee or distributor of GRACELL. 

1.14. “Improvements” shall mean, including but not limited to, any improvements, derivative works, enhancements, technical
advances, modifications, adaptations, new models, or data, including data resulting from failed or successful tests or trials, created based upon or derived from the Licensed Technology. 

1.15. “IND” shall mean (i) an Investigational New Drug Application, as defined in the U.S. Federal Food, Drug and
Cosmetic Act, as amended, and the regulations promulgated thereunder, that is required to be filed with the U.S. Food and Drug Administration before beginning clinical testing of a pharmaceutical product in human subjects or any foreign counterpart
of such Investigational New Drug Application, and any other equivalent investigational new drug application practices applicable in other Licensed Territory (including without limitation the investigational new drug application within National
Medical Products Administration in the PRC) as may be amended from time to time, and (i) all supplements and amendments that may be filed with respect to the foregoing. 

1.16. “IND Approval” shall mean the acceptance (or deemed acceptance) of the filing of an IND by the applicable regulatory
authority in the Licensed Territory. 
 1.17. “Independently Developed IP” shall mean any and all patents, patent
applications, inventions (whether patentable or not), copyrights, works of authorship, trade secrets, know-how, and all other proprietary or confidential information generated, conceived, developed or reduced
to practice (constructively and actually) by or on behalf of GRACELL or its Affiliates, including their employees, agents and contractors, that are not based on or derived from the Licensed Technologies. 

  
 Page 3 of 25 

 1.18. “Intellectual Property Rights” means rights in all inventions,
patents or patent applications (including all kinds of the same such as utility, process, method, or design), copyrights, trademarks, service marks, trade dress, trade secrets, know-how, utility models,
industrial designs, mask works, moral rights, works, or other data or information whether or not protectable under any applicable law in the Licensed Territory, including the right to file for registration or protection for the same and all
renewals, continuations, divisionals, reexaminations, and extensions thereof, whether or not such rights have been applied-for, patented or registered in any jurisdiction. 

1.19. “JSC” shall have the meaning ascribed to it in Section 12.1. 

1.20. “JSC Chair” shall have the meaning ascribed to it in Section 12.1. 

1.21. “License” refers to the license granted under Section 2.1. 

1.22. “Licensed Technology” or “Licensed Technologies” shall mean the information about any process(es),
product(s), machine(s), manufacture, composition of matter, apparatus, kit, or any part thereof, which incorporate, embody, utilize, or are claimed in (i) the Patent and the deliverables listed in Appendix A and Appendix B, which is
incorporated into this Agreement and any updates, renewals, extensions and Improvements developed solely by or on behalf of FUTUREGEN during the Term from the Patent; (ii) any other intellectual properties controlled by FUTUREGEN as of the
Effective Date and during the Term that are related to CLDN18.2 antibodies for the development of engineered or modified immune cell therapies; (iii) any continuations, divisionals, and continuations-in-part, to the extent the claims of the Patent application is directed to subject matter specifically described in the Patent application and the deliverables listed in (i) and (ii) above
and any patents that issue therefrom; (iv) any patents or patent applications that claim priority to the patent applications listed in (i), (ii) or (iii) above, any reissues, re-examinations,
extensions or substitutions of the patents listed in (i), (ii) or (iii) above, and the relevant international equivalents of any of the foregoing; provided, however, Independently Developed IP shall be excluded. For the avoidance of doubt, the
Licensed Technology or Licensed Technologies shall include without limitation the Patent with deliverables listed in Appendix A and Appendix B. 

1.23. “Licensed Territory” shall mean worldwide. 

1.24. “Net Sales” shall mean, with respect to the Patent, the total dollar amount invoiced on sales or other dispositions of
the Patent or the Licensed Technology or the Products by GRACELL or any of its Affiliates or Sublicensees (each, a “Selling Party”) to third parties (other than GRACELL’s Affiliates or Sublicensees), less the following
deductions: 
 (a) allowances for damaged or missing goods, and any discount customary in the trade and actually allowed; 

(b) trade, cash or quantity discounts not already reflected in the amount invoiced, to the extent related to the gross amount billed or
invoiced; 
 (c) price reductions, rebates and administrative fees (including those paid or credited to pharmacy benefit managers,
governmental authorities or otherwise); 

  
 Page 4 of 25 

 (d) shipping costs, including freight, insurance and other transportation charges or costs
incurred in shipping of goods as part of the sales or other dispositions of the Patent or the Licensed Technology or the Products; 
 (e)
sales, use, excise, value-added or similar taxes, customs duties and other governmental fees, charges and surcharges imposed on the sale or other dispositions of the Patent or the Licensed Technology or the Products; 

(f) amounts repaid or credited by reason of rejections, defects, recalls or returns; 

(g) amounts paid or credited for wholesaler chargebacks; 

(h) any receivables that have been included in gross sales and are deemed to be uncollectible according to generally accepted accounting
standards (any such bad debt deductions shall be applied to Net Sales in the period in which such receivables are written off); and 
 (i)
any other deductions actually incurred, allowed, paid, accrued or otherwise specifically allocated to the relevant goods sold or otherwise disposed by the Selling Party in accordance with the applicable accounting standards, in either case,
consistently applied throughout the organization of the applicable Selling Party. 
 All such discounts, allowances, credits, rebates and
other deductions shall be fairly and equitably allocated to the Patent or the Licensed Technology in accordance with the applicable accounting principles. 

Notwithstanding the foregoing, amounts received or invoiced by GRACELL, its Affiliates, or their respective Sublicensees or subcontractors for
the sale or other dispositions of the Patent or the Licensed Technology among GRACELL, its Affiliates or their respective Sublicensees or subcontractors shall not be included in the computation of Net Sales hereunder. For purposes of determining Net
Sales, the applicable Product shall be deemed to be sold when billed or invoiced, provided that if a such Product is delivered to a third party before being invoiced (or is not invoiced), Net Sales will be calculated at the time all the revenue
recognition criteria under the applicable accounting standards are met. 
 Notwithstanding the foregoing, the transfer or other disposition
of the Patent or the Licensed Technology or the Products by GRACELL (x) in connection with the research, development or testing of such Patent or Licensed Technology (including, without limitation, the conduct of clinical trials), (y) for
purposes of distribution as promotional samples, or (z) at nominal cost for indigent or similar public support or compassionate use programs, will not, in any case, be included into Net Sales under this Agreement; provided that the event
described in (x), (y) and (z) is not profitable. 
 1.25. “New Proprietary Technology” shall have the meaning ascribed
to it in Section 7.2. 

  
 Page 5 of 25 

 1.26. “Non-Clinical Validation
Study” shall mean the pre-clinical collection and evaluation of data with respect to the Patent and the Licensed Technology, which data shall establish such scientific evidence that a process is
capable of consistently delivering quality products that shall fit GRACELL’s commercial goal of validating and selecting specific CLDN18.2 antibodies from available antibodies to further identify, manufacture, develop and commercialize novel
immune cell therapies for the treatment of cancer. 
 1.27. “Pivotal Study” shall mean (i) a phase II clinical trial,
or (ii) a human clinical trial approved by appropriate regulatory bodies, the principal purpose of which is to evaluate the effectiveness of a drug for a particular indication in patients with the disease and to determine the common short-term
side effects and risks associated with the drug as required in 21 C.F.R. §312.21(b) or its foreign equivalent (including without limitation the National Medical Products Administration in the PRC). 

1.28. “Product” or “Products” shall mean the cell product or products that GRACELL develops using the
Licensed Technology. 
 1.29. “Reasonable Commercial Efforts” shall mean documented efforts that are consistent with those
utilized by companies of similar size and type to GRACELL that have successfully developed products and services similar to Licensed Technologies in the Field. 

1.30. “Regulatory Approval” shall mean any and all approvals, licenses, permits, registrations or authorizations of or from
any regulatory authority that are necessary to market and sell a pharmaceutical product in any country or other jurisdiction. 
 1.31.
“Royalty Rate” shall have the meaning ascribed to it in Section 4.3. 
 1.32. “Sublicensee” shall have
the meaning ascribed to it in Section 3.1. 
 1.33. “Term” shall have the meaning ascribed to it in Section 2.2.

 1.34. “Upfront Payment” shall have the meaning ascribed to it in Section 4.1. 

1.35. “Valid Claim” shall mean a claim contained in (a) an issued and unexpired Patent or patents described in the
Licensed Technologies which claim has not been found to be unpatentable, invalid, revocable or unenforceable by a decision of a court or other authority of competent jurisdiction in the subject country or jurisdiction, which decision is unappealable
or unappealed within the time allowed for appeal, and has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise, or (b) a Patent or patent application described in the Licensed Technologies that
has not been irretrievably cancelled, withdrawn, abandoned or rejected. 
 ARTICLE 2 LICENSE GRANT AND TERM 

2.1. Subject to all the terms and conditions of this Agreement, FUTUREGEN hereby grants and shall cause to be granted to GRACELL, during the
Term, an exclusive (even as to FUTUREGEN), royalty-bearing license, with the right to grant sublicenses, under the Licensed Technologies to research, develop, use, make, have made, manufacture, have manufactured, sell, have sold, offer for sale,
import, export, promote, market, distribute or commercialize the Licensed Technologies within the Field in and for the Licensed Territory (the “License”). 

  
 Page 6 of 25 

 (a) In the event that FUTUREGEN develops any developments or inventions to the Licensed
Technology that may be useful to GRACELL’s efforts to commercialize the Licensed Technology, FUTUREGEN will promptly notify GRACELL of such developments or inventions and disclose such developments or inventions to GRACELL. FUTUREGEN shall not
disclose or license any such developments or inventions to a third party until after GRACELL had the opportunity to evaluate the same for purposes of licensing such developments or inventions. 

(b) In the event FUTUREGEN or a third party desires to describe in a scholarly or scientific publication, prior to taking any steps to
publishing any such publication, FUTUREGEN shall obtain GRACELL’s prior written consent so that GRACELL can determine whether any Confidential Information of GRACELL is at risk of disclosure or publication. Notwithstanding the foregoing,
FUTUREGEN shall not publish any publication related to the application of the Licensed Technology in the Field. 
 2.2. The term of the
License (the “Term”) shall commence on the Effective Date and shall not expire unless this Agreement is terminated earlier as provided in ARTICLE 9. 

2.3. FUTUREGEN shall provide GRACELL with complete and accurate copies of the FUTUREGEN Know-How within
one (1) month after the Effective Date of this Agreement. The JSC shall establish a reasonable process and schedule for the transfer of additional FUTUREGEN Know-How as required for the performance of any
Party’s obligations or the exercise of any Party’s rights under this Agreement and any other FUTUREGEN Know-How that subsequently comes into existence during the Term in any event at least
semi-annually. FUTUREGEN shall reasonably cooperate with GRACELL in providing GRACELL with copies of such FUTUREGEN Know-How in accordance with the process and schedule agreed upon through the JSC. 

ARTICLE 3 SUBLICENSES 
 3.1.
Subject to the terms and conditions of this Agreement, GRACELL shall have the right to grant sublicenses under the License and at its sole discretion to (i) an Affiliate of GRACELL, which sublicense shall permit the further grant of
sublicenses, or (ii) a third party, which sublicenses shall permit the further grant of sublicenses (the “Sublicensees”). 

ARTICLE 4 PAYMENTS/CONSIDERATION 

4.1. License Upfront Payment 
 (a)
GRACELL shall pay to FUTUREGEN a license upfront fee (the “Upfront Payment”) of [***] dollars ($[***]) within [***] business days of the Effective Date. 

(b) In the event that GRACELL exercises its right to grant any sublicense to a Sublicensee and completes such
sub-licensing in accordance with Section 3.1, GRACELL shall pay to FUTUREGEN a non-refundable sub-licensee fee of
[***]% of any upfront payment received by GRACELL from such Sublicensee for such sub-licensing within [***] days after Gracell receives the relevant payment in full from such Sublicensee. 

  
 Page 7 of 25 

 4.2. Milestone Payment: 

(a) In addition to all other payment required under this Agreement, GRACELL agrees to pay FUTUREGEN milestone payments upon completion of each
milestone event as specified as follows: 
 (i) a non-refundable milestone payment of [***]
dollars ($[***]) upon GRACELL’s written confirmation on the completion of [***]; 
 (ii) a
non-refundable milestone payment of [***] dollars ($[***]) after [***]; 

(iii) a non-refundable milestone payment of [***] dollars ($[***]) upon the IND Approval
of [***]; 
 (iv) a non-refundable milestone payment of [***] dollars ($[***])
upon the launch of [***]; and 
 (v) a non-refundable milestone payment of [***]
dollars ($[***]) upon the BLA approval of [***]. 
 (b) In the event that GRACELL exercises its right to grant any sublicense
to a sublicensee and completes such sub-licensing in accordance with Section 3.1, GRACELL shall pay to FUTUREGEN a non-refundable
sub-licensee fee of [***]% of any tiered milestone payments received by GRACELL from such Sublicensee for such sub-licensing within [***] business days
after Gracell receives the relevant payment in full from such Sublicensee. 
 4.3. Tiered Royalties. Subject to Section 4.4 and 4.5,
GRACELL shall pay royalties to FUTUREGEN, on a Product-by-Product and region-by-region
basis, for the Products sold by Selling Party in the Licensed Territory, calculated by multiplying the applicable Royalty Rate (defined below) by the amount of Net Sales of such Product for each calendar year within [***] days after the
end of such calendar year. The royalty rate (“Royalty Rate”) will be determined as follows: 
 (a) [***] percent
([***]%) of the Net Sales if the Net Sales is less than or equal to [***] dollars ($[***]). 
 (b) [***] percent
([***]%) of the Net Sales if the Net Sales is between [***] dollars ($[***]) and [***] dollars ($[***]). 

(c) [***] percent ([***]%) of the Net Sales if the Net Sales is greater than [***] dollars ($[***]). 

4.4. Royalty Term. Royalties under Section 4.3 shall be payable, on a
region-by-region and Product-by-Product basis, from the period beginning on the date of
the First Commercial Sale of such Product in such region in the Licensed Territory and continuing unless the License is terminated earlier as provided in ARTICLE 9. (the “Royalty Term”) For the avoidance of doubt, on a Product-by-Product and region-by-region basis, royalties shall not be payable on the Net Sales
of the Products occurred after the Royalty Term. 

  
 Page 8 of 25 

 4.5. Royalty Reduction. Notwithstanding anything to the contrary hereunder, on a region-by-region and Product-by-Product basis, (i) if, the Royalty Term lasts more than
[***] years for a Product in a region in the Licensed Territory, then the applicable royalty rate set forth in Section 4.3 shall be reduced by [***]% from the [***] year of the Royalty Term for such Product in such region;
and (ii), if, as a result of (i), a commercialization of a Generic Product occurs in such region, then the applicable royalty rate set forth in (i) shall be additionally reduced by [***]%. 

ARTICLE 5 CONFIDENTIALITY AND PUBLICITY 

5.1. Subject to the Parties’ rights and obligations pursuant to this Agreement, the Parties agree that until the earlier to occur of
(i) the second anniversary of the termination of this Agreement pursuant to ARTICLE 9 or (ii) the date when any patent described in the Licensed Technologies becomes public, each of them: 

(a) will keep confidential and will cause their Affiliates and, in the case of GRACELL, its Sublicensees, to keep confidential, Confidential
Information disclosed to it by the other Party, by taking whatever action the Party receiving the Confidential Information would take to preserve the confidentiality of its own Confidential Information, which in no event shall be less than
reasonable care; and 
 (b) will only disclose that part of the other’s Confidential Information to its officers, employees or agents
that is necessary for those officers, employees or agents who need to know to carry out its responsibilities under this Agreement; and 
 (c)
will not use the other Party’s Confidential Information other than as expressly set forth in this Agreement or disclose the other’s Confidential Information to any third parties under any circumstance without advance written permission
from the other Party; and 
 (d) will, except to the extent that GRACELL retains the surviving License from FUTUREGEN as provided under
Section 9.5, within [***] days of termination of this Agreement, return all the Confidential Information disclosed to it by the other Party pursuant to this Agreement except for one copy which may be retained by the recipient for
archival purposes. 
 5.2. The obligations of confidentiality described above shall not pertain to that part of the Confidential Information
that as established by written records: 
 (a) is already in the recipient’s possession prior to receipt from the disclosing Party; or

 (b) is in the public domain by use and/or publication at the time of receipt from the disclosing Party, or enters into the public domain
through no improper act of the receiving Party; or 
 (c) is developed independently by the receiving Party without reference to the
information of the disclosing Party; or 

  
 Page 9 of 25 

 (d) is properly obtained by receiving Party from a third party with a valid legal right to
disclose such information and such third party is not under a confidentiality obligation to such information to the disclosing Party; or 

(e) is required to be disclosed by law in the opinion of recipient’s attorney, but only after the disclosing Party is given prompt written
notice and an opportunity to seek relief from the demanding authority. 
 5.3. Except as required by law, or as may be necessary to obtain
advice from its respective attorneys, financial advisors, or accountants or for such individuals to perform their duties, neither Party may disclose the financial terms of this Agreement without the prior written consent of the other Party. 

ARTICLE 6 REPORTS 
 6.1.
GRACELL shall, within [***] days after the calendar quarter in which Net Sales first occur, provide FUTUREGEN with a written report, detailing the Net Sales and uses, if any, made by GRACELL, its Sublicensees and Affiliates of Licensed
Technology in the Field. Net Sales of Licensed Technology shall be deemed to have occurred on the date of invoice for such Licensed Technology in the Field. Each such report shall be signed by an officer of GRACELL (or the officer’s designee),
and must include names and addresses of all Sublicensees and the type and amount of any Sublicense income received from each Sublicensee. 
 ARTICLE
7 PATENT PROTECTION AND OWNERSHIP OF IMPROVEMENTS 
 7.1. FUTUREGEN shall advise GRACELL in writing at such time as the Patent
application issued. If GRACELL believes that the Licensed Technology includes any inventions that are or may be patentable in the Field in and for the Licensed Territory, GRACELL shall notify FUTUREGEN, and the Parties together shall consider the
further actions that may be advisable to secure applicable patents. 
 7.2. FUTUREGEN agrees that to the extent that GRACELL, its Affiliates
and subcontractors developed or created anything based upon or arising from the Licensed Technologies, whether alone or jointly with FUTUREGEN, including without limitation, deliverables, know-how, protocols,
products in the Field, whether patentable or not (the “New Proprietary Technology”) following the Effective Date of this Agreement in the Licensed Territory, GRACELL shall be the sole owner of the New Proprietary Technology,
including all Intellectual Property Rights therein, with all rights to apply for, prosecute, direct the filing, prosecution and maintenance of any applications for patents, trademarks and copyrights covering the same in the Licensed Territory.
FUTUREGEN agrees that, if necessary, and at GRACELL’s expense, it shall reasonably cooperate with GRACELL in perfecting GRACELL’s ownership in such New Proprietary Technology by, including but not limited to executing all further documents
requested by GRACELL that may be necessary or advisable to effectuate or perfect GRACELL’s ownership in such New Proprietary Technology.

  
 Page 10 of 25 

 7.3. Except in connection with the performance of activities under this Agreement, FUTUREGEN
shall not (by itself or through any third party), and shall cause its Affiliates and subcontractors (by themselves or through any third party) not to, directly or indirectly, (i) research, develop, manufacture, commercialize or otherwise
exploit any engineered or modified immune cell therapy redirected to CLDN18.2; or (ii) sell, assign, transfer, convey, license, sublicense, covenant not to assert or otherwise grant, or transfer to, any third party, any rights or immunities to
or under the Licensed Technology to conduct such activities described in this Section 7.3. 
 ARTICLE 8 INFRINGEMENT AND LITIGATION

 8.1. Each Party shall promptly notify the other in writing in the event that (a) it obtains knowledge or becomes reasonably
suspicious of activity by third parties infringing or otherwise violating the Intellectual Property Rights in the Licensed Technologies, or (b) it is sued or threatened with an infringement suit, in any country in the Licensed Territory as a
result of activities that concern the Licensed Technologies, and shall supply the other Party with documentation of the infringing activities that it possesses. 

8.2. During the Term of this Agreement: 

(a) GRACELL shall have the first right, but not the obligation, to assert and defend rights in the Licensed Technologies respecting
infringement or other violation of Intellectual Property Rights in the Licensed Technologies within the Field by third parties and in the Licensed Territory using counsel of its own selection. This right includes bringing any legal action for
infringement and defending any counter claim of a third party respecting the Licensed Technologies such as a counter claim or declaratory judgment for invalidity, non-infringement, or unenforceability. If, in
the reasonable opinion of GRACELL’s counsel, FUTUREGEN is required to be a named Party to any such suit for standing purposes, GRACELL may join FUTUREGEN as a Party; provided, however, that (i) FUTUREGEN shall not be the first named Party
in any such action, (ii) the pleadings and any public statements about the action shall state that the action is being pursued by GRACELL and that GRACELL has joined FUTUREGEN as a Party; and (iii) GRACELL shall keep FUTUREGEN reasonably
apprised of all developments in any such action. GRACELL may settle such suits only with FUTUREGEN’s prior written consent, which shall not be unreasonably withheld, conditioned, or delayed. However, FUTUREGEN shall have the right to
participate in any such action through its own counsel and at its own expense. Any recovery shall first be applied to GRACELL’s out of pocket expenses and second shall be applied to FUTUREGEN’s out of pocket expenses, including legal fees.
After those expenses have been fully paid by the recovery, FUTUREGEN shall have the right to further obtain ten percent (10%) of the remaining recovery . 

(b) In the event GRACELL fails to initiate and pursue or participate in the actions described in the preceding paragraph (a) within
[***] days of GRACELL first becoming aware of an infringement or other violation of Intellectual Property Rights in the Licensed Technologies or (b) upon notice by GRACELL to FUTUREGEN that it does not intend to initiate, pursue or
participate in such action(s), whichever is earlier, FUTUREGEN shall have the right to initiate or take over such legal action at its own expense and FUTUREGEN may use the name of GRACELL as a Party in such action. In such case, GRACELL shall
provide reasonable assistance to FUTUREGEN if requested to do so. FUTUREGEN shall keep GRACELL reasonably apprised of all developments in any such action. FUTUREGEN may settle such actions solely through its own counsel. However, in the event that
any such settlement may have a material effect on the License rights granted to GRACELL under this Agreement, FUTUREGEN shall not settle any such action without first consulting with GRACELL and obtaining GRACELL’s prior written consent, which
shall not be unreasonably withheld. Any recovery shall first be applied to FUTUREGEN’s out of pocket expenses and second shall be applied to GRACELL’s out of pocket expenses in pursuing the legal action solely through FUTUREGEN’s
counsel and settled in favor of FUTUREGEN. 

  
 Page 11 of 25 

 8.3. In the event GRACELL is permanently enjoined from exercising its LICENSE under this
Agreement pursuant to an infringement action brought by a third party, or if both GRACELL and FUTUREGEN elect not to undertake the defense or settlement of a suit alleging infringement for a period of [***] months from notice of such suit,
then either Party shall have the right to terminate this Agreement in the country where the suit was filed with respect to the Patent following [***] days’ written notice to the other Party in accordance with the terms of ARTICLE 15.

 ARTICLE 9 TERMINATION 

9.1. GRACELL shall have the right to terminate this Agreement upon written notice to FUTUREGEN: 

(a) in the event FUTUREGEN commits a breach of any provision of this Agreement, including but not limited to the breach of any of the
Representations and Warranties clauses, and such breach is not cured (if capable of being cured) within the [***]-day period after receipt of written notice thereof from GRACELL, or upon receipt of such notice if such breach is not capable of
being cured. 
 (b) in the event of a Force Majeure Event as set forth in Section 17.8. 

(c) at any time and in the event it is determined that none of the Licensed Technologies are patentable subject matter by a non-appealable decision of a court of competent jurisdiction or an applicable patent office administrative tribunal, or all the patents included within LICENSED TECHNOLOGIES are declared invalid by a non-appealable decision of a court of competent jurisdiction or an applicable patent office administrative tribunal. 

9.2. Within [***] days of termination of this Agreement, FUTUREGEN shall return to GRACELL all of GRACELL’s Confidential
Information disclosed by GRACELL, or destroy all of Gracell’s Confidential Information disclosed by GRACELL. 
 9.3. FUTUREGEN shall
have the right to terminate this Agreement upon written notice to GRACELL: 
 (a) in the event GRACELL commits a breach of any provision of
this Agreement and such breach is not cured within the [***]-day period after receipt of written notice thereof from FUTUREGEN. For the avoidance of doubt, in the event there is a dispute between the Parties regarding GRACELL’s payment
obligations under this Agreement, GRACELL shall not be held liable until such dispute is resolved. 
 (b) in the event of a Force Majeure
Event as set forth in Section 17.8. 

  
 Page 12 of 25 

 (c) in the event GRACELL fails to get the IND Approval of [***] by the last day of the
[***] year from GRACELL’s written confirmation of the complete delivery of the deliverables listed in Appendix B; 
 (d) in the
event GRACELL succeeds in getting the IND Approval of [***] but fails to submit the BLA of [***] by the last day of the [***] year from the date GRACELL gets such IND Approval; 

9.4. Except to the extent that GRACELL retains the License from FUTUREGEN as provided under Section 9.5, within [***] days of
termination of this Agreement, GRACELL shall, and shall cause other Selling Party to, return to FUTUREGEN all of FUTUREGEN’s Confidential Information disclosed by FUTUREGEN, or destroy all of FUTUREGEN’s Confidential Information disclosed
by FUTUREGEN. 
 9.5. Upon the expiration or termination (excluding termination by FUTUREGEN pursuant to Section 9.3) of this Agreement,
the License shall survive to the extent necessary to exercise any surviving License right hereunder. Except as expressly provided herein, at the date of such termination, GRACELL shall immediately cease using any of the Licensed Technologies;
provided, however, that a Selling Party may sell any Products actually in the possession of such Selling Party on the effective date of termination. All other rights and obligations of the Parties under this Agreement shall terminate, except as
provided elsewhere under this ARTICLE 9. 
 9.6. Upon the termination of this Agreement, nothing herein shall be construed to release either
Party from any obligation that shall have matured prior to the effective date of such termination. 
 9.7. The following provisions shall
survive any termination: ARTICLE 7, ARTICLE 8, ARTICLE 11, ARTICLE 13, ARTICLE 14. 
 9.8. The rights provided in this ARTICLE 9 shall be in
addition and without prejudice to any other rights and remedies under the law which the Parties may have with respect to any breach of the provisions of this Agreement. 

9.9. Upon the termination of this Agreement, GRACELL will pay FUTUREGEN all payment or considerations as described in ARTICLE 4 (including
license upfront fee, sublicense fee, milestone payment, and royalty payments) already incurred through the date of notice of termination. In addition, GRACELL will pay FUTUREGEN for any activities the Parties mutually agree FUTUREGEN is required to
undertake due to such termination. For the avoidance of doubts, all payment or considerations as described in ARTICLE 4 paid by GRACELL to FUTUREGEN before the termination of this Agreement is non-refundable,
and FUTUREGEN has no obligation to repay such payment or considerations to GRACELL due to the termination of this Agreement. 
 9.10. Waiver
by either Party of one or more defaults or breaches shall not deprive such Party of the right to terminate because of any subsequent default or breach. 

  
 Page 13 of 25 

 9.11. Accrued Obligations; Survival. Neither expiration nor any termination of this
Agreement shall relieve either Party of any obligation or liability accrued prior to such expiration or termination, nor shall the expiration or any termination of this Agreement preclude either Party from pursuing all rights and remedies it may
have under this Agreement, at law or in equity, with respect to breach of this Agreement. In addition, the Parties’ rights and obligations under ARTICLE 5, ARTICLE 9, ARTICLE 15 and ARTICLE 16 of this Agreement shall survive expiration or any
termination of this Agreement. 
 ARTICLE 10 REPRESENTATIONS AND WARRANTIES 

10.1. FUTUREGEN represents and warrants to GRACELL, as of the Effective Date, as follows: 

(a) FUTUREGEN (i) has sufficient, sole and exclusive legal and/or beneficial title or ownership, free and clear from any mortgages,
pledges, liens, security interests, encumbrances, charges or claim of any kind, of and to the Licensed Technologies to grant the License; and (ii) has not granted any right to any third party with respect to the Licensed Technologies that would
conflict with the License or rights granted to GRACELL hereunder. 
 (b) FUTUREGEN has not received any written or oral notice that any third
party has taken any action before any applicable patent office or any court or arbitration tribunal or governmental authority, claiming ownership or license of any Licensed Technologies. 

(c) FUTUREGEN has not received any written or oral notice from any third party asserting that the issued patents described in the Licensed
Technologies are invalid or unenforceable. 
 (d) No reexamination, interference, invalidity, opposition, nullity or similar claim or
proceeding is pending or threatened with respect to the patents described in the Licensed Technologies, and none of such patents existing as of the Effective Date has been adjudged, in a final and
non-appealable decision, invalid, unenforceable or unpatentable by any governmental authority of competent jurisdiction. 

(e) FUTUREGEN has not received any written or oral notice from any third party asserting or alleging that (i) any research, development,
manufacture or commercialization of the Licensed Technologies prior to the Effective Date or any Licensed Technologies infringed or misappropriated the intellectual property rights of such third party, or (ii) the development, manufacture or
commercialization of the Licensed Technologies in the Licensed Territory would infringe or misappropriate the intellectual property rights of such third party. 

(f) No third party is infringing or has infringed any Licensed Technology. 

(g) All maintenance fees, annuity payments, and similar payments relating to the patents described in the Licensed Technologies have been made,
and will be made, in a timely manner. Prior to the Effective Date, FUTUREGEN has not taken action or failed to undertake an action in connection with filing, prosecuting and maintaining such patents in violation of any applicable law. 

(h) FUTUREGEN has complied with all applicable laws in connection with the prosecution of the patents described in the Licensed Technologies,
including the duty of candor owed to any patent office pursuant to such laws. 

  
 Page 14 of 25 

 (i) FUTUREGEN has not entered, and shall not enter, into any agreement with any third party
that is in conflict with the rights granted to GRACELL under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting the rights granted to GRACELL under this Agreement, or that would otherwise
materially conflict with or adversely affect GRACELL’s rights under this Agreement. 
 10.2. Each Party hereby represents and warrants
to the other Party that: (i) it is duly authorized to execute and deliver this Agreement and to perform its obligation hereunder; (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its
terms; (iii) the execution, delivery and performance of this Agreement do not conflict with any agreement, instrument or understanding , oral or written, to which it is a Party or by which it may be bound, nor violate any law or regulation of
any court, government body or administrative or other agency having jurisdiction over it. 
 ARTICLE 11 COVENANTS 

11.1. FUTUREGEN covenants that it will not grant license to others in the Licensed Territory to use, make or sell products or processes in
engineered or modified immune cell therapies redirected to CLDN 18.2 which is not covered by the Licensed Technology and may be similar and/ or compete with the Licensed Technologies in the Field. 

11.2. FUTUREGEN covenants to provide GRACELL, its Affiliates the Licensed Technologies in full and in a timely manner in accordance with
Section 2.3. 
 11.3. FUTUREGEN covenants to provide the GRACELL and its Affiliates with technical support and training, ensuring that
GRACELL and its Affiliates and its Sublicensees fully grasp the Licensed Technology and are capable of independent application of Licensed Technology. A separate agreement may be entered into if GRACELL intends to entrust FUTUREGEN to develop
ancillary products based on the Patent or patents in the Licensed Technologies. 
 11.4. The Parties recognize that each Party may perform
some or all of its obligations or exercise some or all of its rights under this Agreement through one or more Affiliates or subcontractors or, in the case of GRACELL, Sublicensees; provided, in each case, that (a) none of the other Party’s
rights hereunder are diminished or otherwise adversely affected as a result of such delegation or subcontracting, and (b) each such Affiliate, subcontractor or Sublicensee undertakes in writing obligations of confidentiality and ownership of
intellectual properties which are substantially the same as those undertaken by the Parties pursuant to this Agreement; and provided, further, that such Party shall at all times be fully responsible for the performance by such Affiliate,
subcontractor or Sublicensee of the obligations with respect to confidentiality and ownership of intellectual properties. 
 ARTICLE 12
GOVERNANCE AND JOINT STEERING COMMITTEE 
 12.1. Within [***] days after the Effective Date, the Parties shall establish a
cross-functional joint steering committee (the “JSC”) composed of three (3) representatives from each Party. The JSC may, from time to time, establish subcommittees as it deems necessary to further the purposes of this
Agreement. Each Party shall appoint its respective representatives to the JSC from time to time, and may change its representatives, in its sole discretion, effective upon notice to the other Party designating such change. The representatives from
each Party shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with this Agreement. One (1) of the GRACELL representatives on the JSC shall be designated the chair of the JSC (the
“JSC Chair”). The JSC Chair will be responsible for calling meetings of the JSC, circulating agendas and performing administrative tasks required to assure efficient operation of the JSC. 

  
 Page 15 of 25 

 12.2. The JSC shall have the following functions and powers: 

(a) review, discuss and coordinate the Parties’ activities under this Agreement; 

(b) review, discuss and coordinate the overall strategy for the research, development and commercialization of the Patent and the Licensed
Technologies in the Licensed Territory; 
 (c) discuss the progress of the research and development programs, including any pre-clinical validation protocols; 
 (d) oversee and coordinate the
on-going disclosure, sharing and/or transfer of any new inventions or new intellectual property works, including any New Proprietary Technology or Independently Developed IP, generated in or related to the
research and development programs; 
 (e) establish subcommittees, direct and oversee any operating subcommittee on all significant issues,
and resolve disputed matters that may arise at the subcommittees; 
 (f) perform such other functions as appropriate to further the purposes
of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing. 
 12.3. The JSC will meet at least
once every quarter during the Term. The JSC may conduct such meetings by telephone, videoconference, or in person. Each Party may call special meetings of the JSC with at least [***] Business Days’ prior written notice, or a shorter time
period in exigent circumstances, to resolve particular matters requested by such Party that are within the purview of the JSC. Meetings of the JSC are effective only if at least one (1) representative of each Party participates in such meeting.
Each Party may invite a reasonable number of participants, in addition to its representatives, to attend JSC meetings in a non-voting capacity; provided, that if either Party intends to have any third party
(including any consultant) attend such a meeting, such Party shall provide prior written notice to the other Party. Such Party shall ensure that such third party is bound by confidentiality and non-use
obligations consistent with the terms of this Agreement. Each Party is responsible for its own expenses incurred in connection with participating in and attending all such meetings. The JSC Chair or his/her designee shall keep minutes of each JSC
meeting that records in writing all decisions made, action items assigned or completed and other appropriate matters. The JSC Chair shall send meeting minutes to all members of the JSC promptly after a meeting for review. Each member shall have
[***] Business Days from receipt to comment on and to approve the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify JSC that he/she does not approve of the
minutes, the minutes shall be deemed to have been approved by such member. 

  
 Page 16 of 25 

 12.4. Decisions. The JSC will endeavor to make decisions by consensus, with the
representatives of each Party having, collectively, [***]. If the JSC cannot reach consensus or a dispute arises that cannot be resolved within the JSC, either Party may refer such dispute to the Executive Officers for resolution. Such
Executive Officers will use good faith efforts to resolve promptly such matter, which good faith efforts will include at least one meeting between such Executive Officers within [***] Business Days after the JSC’s submission of such
matter to them. If consensus cannot be reached with respect to a decision within [***] Business Days after attempted resolution by the Executive Officers, then [***]. 

12.5. Authority. The JSC, the JSC Chair, and each subcommittee has only the powers assigned expressly to it in this Agreement, and does
not have any power to amend, modify, or waive compliance with this Agreement. Each Party retains the rights, powers and discretion granted to it under this Agreement and neither Party may delegate or vest such rights, powers, or discretion in the
JSC or subcommittee unless expressly provided for in this Agreement or the Parties expressly so agree in writing. The JSC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JSC shall be in
contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JSC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JSC. 

12.6. Discontinuation of JSC. The JSC will continue until the expiration or termination of the Term, at which time the JSC shall be
promptly disbanded with immediate effect. 
 12.7. Alliance Manager. Within [***] days following the Effective Date,
each Party shall also appoint an individual to act as the alliance manager for such Party (each, an “Alliance Manager”). Each Alliance Manager shall thereafter be permitted to attend meetings of the JSC and any sub-committee as a nonvoting observer. The Alliance Managers shall be the primary point of contact for the Parties regarding the collaboration activities contemplated by this Agreement and shall help facilitate all
such activities hereunder. 
 ARTICLE 13 INDEMNITY 

13.1. FUTUREGEN hereby indemnifies Gracell, its Affiliates and their respective directors, officers, employees, agents, successors and
assignees against (each, a “Gracell Indemnitee”) and agrees to hold each of them harmless from any and all damage, loss, liability and expense (including reasonable expenses of investigation and reasonable attorneys’ fees and
expenses in connection with any action, suit or proceeding whether involving a third party claim or a claim solely between the Parties hereto and any incidental, indirect or consequential damages, losses, liabilities or expenses, and any lost
profits or diminution in value) (“Losses”), incurred or suffered by any Gracell Indemnitee arising out of any misrepresentation or breach of warranty (determined without regard to any qualification or exception contained therein
relating to materiality or material adverse effect or any similar qualification or standard, including specified dollar thresholds) or breach of covenant or agreement made or to be performed by FUTUREGEN pursuant to this Agreement regardless of
whether such Losses arise as a result of the negligence, strict liability or any other liability under any theory of law or equity of, or violation of any law by, FUTUREGEN, any of its Affiliates or any of their respective directors, officers,
employees, agents, successors and assignees. 

  
 Page 17 of 25 

 ARTICLE 14 TAXES 

14.1. Taxes on Income. Except as otherwise provided in this ARTICLE 14, each Party shall be solely responsible for the payment of all
taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. 
 14.2.
Withholding Taxes. Each Party shall be entitled to deduct and withhold from any payment to be made by such Party (the “Payor”) to the other Party (the “Payee”) hereunder the amount of any tax, levy, impost,
duty or other charge or withholding of a similar nature (“Tax”) required by Applicable Laws and the relevant amounts payable to the Payee hereunder shall be reduced by the amount of Taxes deducted and withheld, which shall be
treated as paid to the Payee in accordance with this Agreement. To the extent that the Payor is required to deduct and withhold Taxes on any payments under this Agreement, the Payor shall pay the amounts of such Taxes to the proper governmental
authority in a timely manner and the Payor shall promptly provide the Payee with the relevant receipts issued by the applicable governmental authority with respect to such deduction or withholding. 

14.3. VAT. All payments due to the Payee from the Payor hereunder are inclusive of, and without further payment by the Payor of, any
value-added tax (including, for greater certainty, any goods and services tax, harmonized sales tax and any similar provincial sales tax) (“VAT”) required by any applicable laws. The Payee shall be responsible for the payment of all
VAT applicable to the transactions contemplated by this Agreement and shall file all required VAT tax returns. To the extent any VAT is required by applicable laws to be withheld from any amounts payable to the Payee under this Agreement or any
other agreement herein, such amounts payable shall be reduced by the amount of VAT withheld, which shall be treated as paid to the Payee in accordance with this Agreement. The Payee shall cooperate, to the extent reasonably required, with the filing
of any such VAT tax returns. If the Payee determines that it is required to report any such tax, the Payor shall promptly provide the Payee with applicable receipts and other documentation necessary for such report. 

ARTICLE 15 NOTICES 
 15.1.
Any payment, notice or other communication required by this Agreement (a) shall be in writing; (b) may be delivered personally, sent via electronic mail, or sent by reputable overnight courier with written verification of receipt;
(c) shall be sent to the following addresses or to such other address as such Party shall designate by written notice to the other Party, and (d) shall be effective upon receipt: 

 

			
	if to FUTUREGEN:	  	 FutureGen Biopharmaceutical Co., Ltd.

[***]
 Attention: [***]

Email: [***]

		
	with a copy to:	  	 Attention: [***]
 Email:
[***]

  
 Page 18 of 25 

			
	if to GRACELL:	  	 Gracell Biotechnologies (HK) Limited

[***]
 Attention: [***]

Email: [***]

		
	with a copy to:	  	 Attention: [***]
 Email:
[***]

 ARTICLE 16 LAWS, FORUM AND REGULATIONS 

16.1. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the People’s Republic of China
without reference to conflict of laws principles or statutory rules of arbitration included therein. 
 16.2. Any Dispute arising under this
Agreement or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement may be submitted by either Party to arbitration. Any dispute shall be submitted to the Shanghai International Economic and Trade
Arbitration Commission in Shanghai for arbitration in accordance with its rules. The arbitral award shall be final and binding on the Parties. 

ARTICLE 17 MISCELLANEOUS 

17.1. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and
permitted assigns. 
 17.2. This Agreement constitutes the entire agreement of the Parties relating to the Licensed Technologies, and all
prior representations, agreements and understandings, written or oral, are merged into this Agreement and are superseded by this Agreement. 

17.3. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction,
such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had
been executed without the invalidated, unenforceable or illegal part. The Parties shall use their Reasonable Commercial Efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) in a way
that, to the extent practicable and legally permissible, implements the original intent of the Parties. 
 17.4. Article headings are
inserted for convenience of reference only and do not form a part of this Agreement. 
 17.5. No person not a Party to this Agreement,
including any employee of either Party to this Agreement, shall have or acquire any rights by reason of this Agreement. The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement shall be construed
as creating any agency, partnership, joint venture or other form of joint enterprise, employment, or fiduciary relationship between the Parties, and neither Party shall have authority to contract for or bind the other Party in any manner whatsoever.

  
 Page 19 of 25 

 17.6. This Agreement may not be amended or modified except by written agreement executed by
each of the Parties. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by either Party without written consent of the other Party, which consent shall not be unreasonably withheld, conditioned, or
delayed, except each Party may, without consent of the other Party, assign or otherwise transfer this Agreement and its rights and obligations hereunder in whole or in part: (a) to any Affiliate; or (b) in connection with a Change of
Control. Any permitted assignee shall assume in writing all assigned obligations of its assignor under this Agreement. The Party making any assignment or other transfer permitted under this Section 17.6 shall provide prompt written notice to
the other Party of such assignment or transfer. 
 17.7. The failure of any Party hereto to enforce at any time, or for any period of time,
any provision of this Agreement shall not be construed as a waiver of either such provision or of the right of such Party thereafter to enforce each and every provision of this Agreement. 

17.8. Neither Party shall be liable or responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for
any failure or delay in fulfilling or performing any terms of this Agreement, including any obligation to timely make any payment hereunder, when and to the extent such failure or delay is caused by: (a) acts of nature; (b) flood, fire, or
explosion; (c) war, terrorism, invasion, riot, or other civil unrest; (d) embargoes or blockades in effect on or after the Effective Date of this Agreement; (e) national or regional emergency; (f) strikes, labor stoppages or
slowdowns, or other industrial disturbances; (g) any passage of law or governmental order, rule, regulation or direction, or any action taken by a governmental or public authority, including imposing an embargo, export or import restriction,
quota, or other restriction or prohibition; or (h) national or regional shortage of adequate power or telecommunications or transportation facilities (each of the foregoing, a “Force Majeure Event”); in each case, provided that
(x) such event is outside the reasonable control of the affected Party; (y) the affected Party provides prompt written notice to the other Party, stating the period of time the occurrence is expected to continue; and (iii) the
affected Party uses diligent efforts to end the failure or delay and minimize the effects of such Force Majeure Event. GRACELL may terminate this Agreement if a Force Majeure Event affecting FUTUREGEN continues substantially uninterrupted for a
period of [***] days or more. Unless GRACELL terminates this Agreement pursuant to the preceding sentence, all dates by which GRACELL must perform any act or on which a GRACELL obligation is due shall automatically be extended for a period up
to the duration of the Force Majeure Event. 
 17.9. The Parties agree that this Agreement may be executed and delivered by facsimile,
electronic mail, internet, or any other suitable electronic means, and the Parties agree that signatures delivered by any of the aforementioned means shall be deemed to be original, valid, and binding upon the Parties. 

17.10. This Agreement may be executed in counterparts, including by transmission of facsimile or PDF copies of signature pages to the Parties
or their representative legal counsel, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. 

  
 Page 20 of 25 

 17.11. The Parties agree that they have been represented by counsel during the negotiation
and execution of this Agreement and, therefore, waive the application of any applicable law or rule of construction providing that ambiguities in an agreement will be construed against the Party drafting such agreement. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 Page 21 of 25 

 IN WITNESS WHEREOF, the Parties hereto have caused this
Agreement to be executed by their duly authorized representatives. 
  

			
	FutureGen Biopharmaceutical Co., Ltd.
		
	By:	 	 /s/ Zhaoyu Jin

	Name:	 	ZHAOYU JIN
	Title:	 	CEO

 Signature Page to Exclusive License Agreement 

 IN WITNESS WHEREOF, the Parties hereto have caused this
Agreement to be executed by their duly authorized representatives. 
  

			
	Gracell Biotechnologies (HK) Limited
		
	By:	 	 /s/ Wei Cao

	Name:	 	Wei Cao
	Title:	 	CEO

 Signature Page to Exclusive License Agreement 

 Appendix A 

[***] 

  
 Appendix A 

 Appendix B 

[***] 

  
 Appendix BEX-4.18

 Exhibit 4.18 

Certain confidential information contained in this document, marked by [***], has been omitted because such information is both not material and is the
type that Gracell Biotechnologies Inc. Company customarily and actually treats that as private or confidential. 
  
 

 
 MANUFACTURING SERVICES AGREEMENT 

This Manufacturing Services Agreement (the “Agreement”) is executed on March 31, 2021 and takes into effect on
April 1, 2021 (the “Effective Date”) between Lonza Houston, Inc., 14905 Kirby Drive, Pearland, TX 77047, USA (“LONZA”), Suzhou Gracell Biotechnologies Co., Ltd. (“Gracell Suzhou”), Building 12,
Zone B, Phase II, Biomedical Industrial Park, No. 218 Sangtian Road, Suzhou Industrial Park, Suzhou, Jiangsu Province, China 215123, and Gracell Biopharmaceuticals, Inc., 1209 Orange Street, City of Wilmington, County of New Castle, Delaware,
USA 19801 (“Gracell US”, together with Gracell Suzhou, “CLIENT”) (each of LONZA and CLIENT, a “Party” and, collectively, the “Parties”). 

RECITALS 
 A. LONZA
operates a multi-client production facility located at 14905 Kirby Drive, Pearland, TX 77047, USA, and/or such other location as LONZA may, in accordance with Sections 2.7 and 2.8, designate in writing from time to time (the
“Facility”). 
 B. CLIENT desires to have LONZA produce certain Product(s) (as defined below) intended for therapeutic use
in humans, and LONZA desires to produce such Product(s). 
 C. CLIENT desires to have LONZA conduct work according to individual Statements
of Work, as further defined below. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants hereinafter
set forth, LONZA and CLIENT, intending to be legally bound, hereby agree as follows: 
 AGREEMENT 

 

	1.	 DEFINITIONS 

When used in this Agreement, capitalized terms shall have the meanings as defined below and throughout the Agreement. Unless the context
indicates otherwise, the singular will include the plural and the plural will include the singular. 
  

	 	1.1.	 “Acceptance Period” shall have the meaning set forth in Section 5.2.1.

  

	 	1.2.	 “Affiliate” means, with respect to either Party, any other corporation or business entity that
directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, the term “control” and, with correlative meanings, the terms
“controlled by” and “under common control with” mean direct or indirect ownership of more than fifty percent (50%) of the securities or other ownership interests representing the equity voting stock or general partnership or
membership interest of such entity or the power to direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise. 

	 	1.3.	 “Background Intellectual Property” means any Intellectual Property either (i) owned or
controlled by a Party prior to the Effective Date or (ii) not invented, generated, developed, acquired or derived from or in connection with this Agreement but owned or controlled by a Party during the term of the Agreement.

  

	 	1.4.	 “Batch” means a specific quantity of Product that is intended to have uniform character and
quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture. 

  

	 	1.5.	 “Batch Records” means the production record pertaining to a Batch. 

 

	 	1.6.	 “cGMP” or “GMP” means the applicable regulatory requirements, as amended from
time to time, for current good manufacturing practices, including without limitation those promulgated by (i) the FDA under the United States Federal Food, Drug and Cosmetic Act, 21 C.F.R. §§ 210 et seq., or (b) the European
Medicines Agency or under the European Union guide to good manufacturing practice for medicinal products. 

  

	 	1.7.	 “cGMP Batch” means any Batch which is required under the relevant Statement of Work to
be manufactured in accordance with cGMP. 

  

	 	1.8.	 “Cancellation Fee” has the meaning set forth in Section 4.5. 

 

	 	1.9.	 “Change Order” has the meaning set forth in Section 2.2. 

 

	 	1.10.	 “CLIENT Development Materials” has the meaning set forth in Section 2.3.

  

	 	1.11.	 “CLIENT Materials” means the CLIENT Development Materials and the CLIENT Production
Materials. 

  

	 	1.12.	 “CLIENT Parties” has the meaning set forth in Section 15.1. 

 

	 	1.13.	 “CLIENT Personnel” has the meaning set forth in Section 4.10.1. 

 

	 	1.14.	 “CLIENT Production Materials” has the meaning set forth in Section 4.1.

  

	 	1.15.	 “CLIENT’s FasTCAR Technology” means all technical,
scientific and other know-how and information, trade secrets, knowledge, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, designs, drawings,
assembly procedures, apparatuses, specifications, data, results and other material, including pharmaceutical, biological, chemical, pharmacological, toxicological, physical and
analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology, in each case (whether or
not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed in connection with FasTCARTTM. 

  
 2 

	 	1.16.	 “Commencement Date” means the date set forth in the relevant Statement of Work for the
commencement of Services, including the production of the Product. 

  

	 	1.17.	 “Confidential Information” has the meaning set forth in Section 10.1.

  

	 	1.18.	 “Disapproval Notice” shall have the meaning set forth in Section 5.2.1.

  

	 	1.19.	 “Engineering Batch” means a Batch generated during an engineering run in order to demonstrate
the transfer of the Process to the Facility. 

  

	 	1.20.	 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereof.

  

	 	1.21.	 “First Statement of Work” has the meaning set forth in Section 2.1.

  

	 	1.22.	 “Force Majeure Event” has the meaning set forth in Section 17.2. 

 

	 	1.23.	 “Forecast” has the meaning set forth in Section 6.1. 

 

	 	1.24.	 “Indemnitee” has the meaning set forth in Section 15.3.1. 

 

	 	1.25.	 “Indemnitor” has the meaning set forth in Section 15.3.1. 

 

	 	1.26.	 “Intellectual Property” means all worldwide patents, copyrights, trade secrets, know-how, technical data, trademarks, trade names, service marks, logos and other corporate identifiers, design right, confidential or proprietary information, and all other intellectual property rights, including
all applications and registrations with respect thereto. 

  

	 	1.27.	 “LONZA Operating Documents” means the corporate standards, batch records, standard operating
procedures, electronic programs and files, raw material specifications, protocols, validation documentation, and supporting documentation used by LONZA, such as environmental monitoring, for operation and maintenance of the Facility and LONZA
equipment used in the process of producing the Product, excluding any of the foregoing that is unique to the manufacture of Product. 

  

	 	1.28.	 “LONZA Parties” has the meaning set forth in Section 15.2. 

 

	 	1.29.	 “LONZA Production Materials” has the meaning set forth in Section 4.4.

  

	 	1.30.	 “Losses” has the meaning set forth in Section 15.1. 

 

	 	1.31.	 “Materials” means all raw materials and supplies to be used in the production of a Product.

  

	 	1.32.	 “Minimum Capacity” has the meaning set forth in Section 6.1. 

  
 3 

	 	1.33.	 “Process” means the manufacturing process for a Product. 

 

	 	1.34.	 “Product” has the meaning set forth in the relevant Statement of Work. 

 

	 	1.35.	 “Product Warranties” has the meaning set forth in Section 5.2.1. 

 

	 	1.36.	 “Project Documentation” means the compilation of documentation generated
by LONZA in preparation of and during the performance of a given SOW, including, without limitation, executed Batch Records, component records, test records and test record forms, certificates of analysis, study protocols, study summary reports,
deviation reports, laboratory investigations, environment excursions, formulation records, and other related documents. 

  

	 	1.37.	 “Production Rerun” has the meaning set forth in Section 5.4.1. 

 

	 	1.38.	 “Quality Agreements” has the meaning set forth in Section 2.9.

  

	 	1.39.	 “Recall” has the meaning set forth in Section 5.5.1. 

 

	 	1.40.	 “Regulatory Approval” means the approval by the FDA or other applicable governmental authority
to market and sell the Product in the applicable markets. 

  

	 	1.41.	 “Remaining CLIENT Property” has the meaning set forth in Section 7.2.

  

	 	1.42.	 “SIAC” has the meaning set forth in Section 17.14. 

 

	 	1.43.	 “Services” means the activities to be performed by LONZA, its Affiliates and/or any approved
Third Party subcontractor under the relevant Statement of Work. 

  

	 	1.44.	 “SOP” means standard operating procedure. 

 

	 	1.45.	 “Specifications” means the Product specifications set forth in the certificate of analysis,
the Quality Agreement or otherwise by the Parties, in writing, in connection with the production of a particular Batch of Product hereunder, including without limitation the specification of the Materials, the manufacturing specifications,
directions and processes, the storage requirements, and all other specifications for the Product; provided that Specifications for Engineering Batches shall be non-binding targets for reference only.

  

	 	1.46.	 “Statement of Work” or “SOW” means a plan to develop a
Process or Product that is attached hereto as Appendix A or later becomes attached through an amendment by the Parties. 

  

	 	1.47.	 “Supply Failure” has the meaning set forth in Section 4.5. 

  
 4 

	 	1.48.	 “Technology Transfer” means the transfer of documentation, specifications, and production
process by CLIENT to LONZA for the development of the Project Documentation for the manufacture of the Product specifically for CLIENT. For the avoidance of doubt, Technology Transfer does not constitute the transfer of the ownership of the relevant
technology, Intellectual Property, documentation or information from CLIENT or its Affiliate to LONZA or LONZA’s Affiliate, and CLIENT expressly retains the ownership of the relevant technology, Intellectual Property, documentation and
information.  

  

	 	1.49.	 “Third Party” means any party other than LONZA, CLIENT or their respective Affiliates.

  

	2.	 STATEMENTS OF WORK—PROCESS
AND PRODUCT DEVELOPMENT; PROCESS OR PRODUCT MANUFACTURE 

2.1 Statement of Work. Prior to performing Technology Transfer, or Process or Product manufacture, the Parties
shall collaborate to develop a Statement of Work, describing the activities to be performed by the Parties, or to be subcontracted by LONZA to Third Parties in accordance with Section 17.11. In the event of a conflict between the terms and
conditions of this Agreement and any Statement of Work, the terms and conditions of this Agreement shall control, unless a Statement of Work expressly and specifically amends or disclaims the conflicting language and signed by both LONZA and CLIENT.
The first Statement of Work, which is attached hereto, is numbered Appendix A-1 and is hereby incorporated and made a part of this Agreement (the “First Statement of Work”). It is contemplated
that each separate project shall have its own Statement of Work. As each subsequent Statement of Work is agreed to by the Parties, each shall state that it is to be incorporated and made a part of this Agreement and shall be consecutively numbered
as A-2, A-3, etc. 
 2.2
Modification of Statement of Work. Should CLIENT desire to change a Statement of Work or to include additional Services to be provided by LONZA, CLIENT may propose to LONZA an amendment to the Statement of Work with the desired changes or
additional Services (“Change Order”). LONZA shall consider CLIENT’s request in good faith. If LONZA determines that it has the resources and capabilities to accommodate such Change Order, LONZA shall prepare a modified version
of the relevant Statement of Work reflecting such Change Order (including, without limitation, any changes to the estimated timing, charges or scope of a project) and shall submit such modified version of the Statement of Work to CLIENT for review
and comment. The modified Statement of Work shall be binding on the Parties only if it refers to this Agreement, states that it is to be made a part thereof, and is signed by both Parties. Whereafter such modified version of the Statement of Work
shall be deemed to have replaced the prior version of the Statement of Work. Notwithstanding the foregoing, if a modified version of the Statement of Work is not agreed to by both Parties, the existing Statement of Work shall remain in effect. 

  
 5 

 2.3 CLIENT Deliverables. Within the time period
specified in a Statement of Work, CLIENT shall provide LONZA with (a) the materials that are not commercially available in the U.S. and CLIENT is responsible for delivering to LONZA under the relevant Statement of Work, and any handling
instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for LONZA’s performance under the Statement of Work, and (b) any other protocols, SOPs and other information and documentation in
possession or control of CLIENT and necessary for LONZA’s performance of the Statement of Work, and for LONZA’s preparation of the Project Documentation in conformance with cGMP, including, without limitation, process information, SOPs,
development data and reports, quality control assays, raw material specifications (including vendor, grade and sampling/testing requirements), product and sample packaging and shipping instructions, and product specific cleaning and decontamination
information, (collectively, the “CLIENT Development Materials”). For the avoidance of doubt, LONZA shall procure other materials, protocols, SOPs, information and documentation required for the performance of the relevant
Statement of Work, except for CLIENT Development Materials. If CLIENT does not provide the CLIENT Development Materials within the time period specified in the relevant Statement of Work, then CLIENT shall be responsible for any actual and
reasonable costs incurred by LONZA arising from such failure, provided that LONZA shall use commercially reasonable efforts to minimize such costs. It is hereby agreed that CLIENT Development Materials, to the extent such are maintained as
Confidential Information or proprietary information by CLIENT, are the proprietary and Confidential Information of CLIENT and shall be used by LONZA only for the purpose of performing LONZA’s obligations under this Agreement and the relevant
Statement of Work. 
 2.4 Performance by LONZA. Subject to the provision by CLIENT of the CLIENT Development
Materials pursuant to Section 2.3, LONZA shall use commercially reasonable efforts to diligently perform, directly or, subject to the terms of the Statement of Work, through a Third Party subcontractor appointed in accordance with
Section 17.11, the work described in the relevant Statement of Work in a professional and workmanlike manner in accordance with the terms of this Agreement. LONZA shall provide the Services and perform its obligations under this Agreement and
the relevant Statement of Work in compliance with all applicable laws, regulations and standards, including without limitation, those related to data privacy, cGMP standards, good laboratory practice, good clinical practice, distortion and storage
practices. LONZA shall promptly notify CLIENT of any delay that arise during the performance of the relevant Statement of Work. For the avoidance of doubt, any delay of the relevant Commencement Date or the scheduled delivery date by more than
[***] days shall be considered a material delay of the relevant Statement of Work. 
 2.5 Engineering
Batches. LONZA shall manufacture Engineering Batches in accordance with the relevant Statement of Work. Both Parties shall discuss and agree on the price for each Engineering Batch. LONZA shall use commercially reasonable efforts to minimize the
number of Engineering Batches that it needs to manufacture prior to the manufacturing of cGMP Batches set forth in Section 2.6. CLIENT shall have the right to make whatever further use of the Engineering Batches as it shall determine, provided
that CLIENT pays for such Batches at a price mutually agreed to between the Parties in writing and such use is not for human use, and upon such payment, all right and title to, and interest in, the Engineering Batch shall be transferred from LONZA
to CLIENT. LONZA makes no warranty that Engineering Batches will meet cGMP or the Specifications. Regardless of whether any Engineering Batch meets cGMP or the Specifications, CLIENT shall pay to LONZA the price for such Engineering Batch plus the
cost of any materials and any materials handling fee associated with such Engineering Batches, for which CLIENT has not previously paid. In the event that CLIENT does not use the Engineering Batches, LONZA shall dispose of such Engineering Batches
according to LONZA’s standard procedure at its own expense. 

  
 6 

 2.6 cGMP Batches. LONZA shall, in accordance with the terms of
this Agreement and the Quality Agreement, manufacture at the Facility and release to CLIENT, cGMP Batches that comply with the Process, cGMP and the Specifications, together with a certificate of analysis; provided, however, that manufacturing of
cGMP Batches shall not commence until at least one (1) successful Engineering Batch has been manufactured in compliance with cGMP and Specifications. Prior to the commencement of manufacturing of cGMP Batches, LONZA shall review the
manufacturing and testing specifications provided by CLIENT. In the event that there is a material difference in the manufacturing and testing specifications provided by CLIENT as compared with the process results demonstrated during the manufacture
of Engineering Batches, the Parties shall meet to discuss in good faith a revision to the Batch price to reflect such difference. 

2.7 Affiliates. An Affiliate of LONZA may, in accordance with Section 17.12, execute a Statement of Work
with CLIENT pursuant to this Agreement and submit invoices to CLIENT under such Statement of Work. Under such circumstances, all references in this Agreement to LONZA shall be deemed to be to the applicable Affiliate of LONZA with respect to
(i) that particular Statement of Work or (ii) the relevant portions of that particular Statement of Work under which such Affiliate will be performing specified Services. The Affiliate shall be entitled to enforce this Agreement with
respect to such Statement of Work, or as applicable the relevant portions of such Statement of Work, in its own name as an intended third party beneficiary and the Affiliate shall be liable to CLIENT for any obligations and liabilities undertaken
pursuant to such Statement of Work and subject to the terms of this Agreement. LONZA shall ensure that LONZA’s Affiliate(s) perform its obligations pursuant to the terms of this Agreement. Notwithstanding the foregoing, LONZA shall remain fully
liable for the performance of its Affiliates. 
 2.8 Facility. All Process and Services shall be
performed at the Facility, or a facility of a LONZA Affiliate that executed a Statement of Work with CLIENT in accordance with Section 2.7, unless otherwise agreed in writing by CLIENT. LONZA shall, at its own expense, provide and maintain all
labor, plant, equipment and Services necessary to enable LONZA and/or its Affiliate to fulfil all obligations under cGMP, this Agreement, the Quality Agreement and the Statements of Work, including without limitation the manufacturing of the
Product. 
 2.9 Quality Agreement. The Parties and/or their applicable Affiliates shall enter into one
or more agreements covering the Product(s), containing the policies, procedures and standards that the Parties shall coordinate and implement in the operational and quality assurance activities and for regulatory compliance objectives contemplated
under this Agreement (collectively, the “Quality Agreements”). 
 2.10 Non-exclusivity. The Product under this Agreement shall be provided on a non-exclusive basis and CLIENT reserves the right to manufacture the Product for itself and to
purchase the Product and similar products from any other Third Parties. CLIENT is not obligated to purchase any minimum or specific quantity or dollar amount of Product under this Agreement. Specific Product quantities and Product pricing will be
further specified under the respective SOWs. 

  
 7 

	3.	 TECHNOLOGY TRANSFER 

3.1 Based on the information provided by CLIENT and including the Process definition or changes developed by LONZA
pursuant to any applicable Statement of Work, LONZA shall use commercially reasonable efforts to prepare the Project Documentation for the Process in accordance with the relevant Statement of Work. CLIENT shall inform LONZA of any specific
requirements CLIENT may have relating to the Project Documentation, including, without limitation, any information or procedures CLIENT wishes to incorporate therein. If LONZA intends to include in the Project Documentation the use of any assay,
medium, or other technology that is not commercially available, LONZA shall inform CLIENT of such intention and the Parties shall meet to discuss and attempt to agree in good faith on the terms of use of such
non-commercially available Materials or technology in the Process. The applicable Project Documentation, as set forth in the SOW, shall be completed and delivered by LONZA at completion of a Batch. 

3.2 CLIENT shall reasonably cooperate with LONZA to assist LONZA to develop the Project Documentation and Process,
including, without limitation, providing LONZA with additional information and procedures as LONZA may reasonably require to create the Project Documentation, Process, and/or any of the following: (i) manufacturing process information, SOPs,
and development reports, (ii) quality control assays, (iii) Specifications of raw Materials (including vendor, grade and sampling/testing requirements), (iv) Product and sample packaging and shipping instructions, (v) Product-specific
cleaning and decontamination information. 
 3.3 LONZA shall deliver a draft version of the applicable portions of the
Project Documentation to CLIENT for its review and approval in accordance with the schedule set forth in the Statement of Work. CLIENT shall notify LONZA in writing of any objections it has to such draft Project Documentation, and upon such
notification, representatives of LONZA and CLIENT shall meet promptly to resolve such objections. Upon CLIENT’s written acceptance of the draft Project Documentation, or in the event that CLIENT does not submit a written notice setting forth
CLIENT’s objections to the draft Project Documentation within [***] business days following the receipt of such draft by CLIENT, such draft shall be deemed to have been approved by CLIENT. 

3.4 The Process, Project Documentation, Specifications, and any improvements or modifications thereto developed during
the term of this Agreement, but excluding any LONZA Operating Documents or Confidential Information of LONZA included in any of the foregoing, shall be deemed CLIENT’s property and Confidential Information and subject to the provisions set
forth in Article 10. CLIENT shall be permitted to use the Process and/or the Project Documentation to manufacture and sell Product; provided, however, that if the Process and/or the Project Documentation incorporates or contains any Intellectual
Property of LONZA or Confidential Information of LONZA, prior to any disclosure of such Intellectual Property or Confidential Information of LONZA to, or use by, a Third Party manufacturer, CLIENT shall obtain LONZA’s written consent to such
disclosure, which consent shall not be unreasonably withheld, delayed or conditioned. 

  
 8 

	4.	 MANUFACTURE OF PRODUCT; ORDER
PROCESS; DELIVERIES 

 4.1 CLIENT Deliverables.
Within any time period agreed to in any applicable Statement of Work, CLIENT shall provide LONZA with the Materials that are not commercially available in the U.S. and listed in the Statement of Work required to be supplied by CLIENT for the
production of the Product, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the performance of the Statement of Work (collectively, the “CLIENT
Production Materials”). For the avoidance of doubt, LONZA shall procure other materials, handling instructions, protocols, SOPs, information and documentation required for the performance of the relevant Statement of Work, except for CLIENT
Production Materials. It is hereby agreed that CLIENT Production Materials are the proprietary and Confidential Information of CLIENT and shall be used by LONZA solely for the purpose of this Agreement. 

4.2 Commencement Date. The Statement of Work shall include a Commencement Date agreed upon by the Parties. 

4.3 Manufacture by LONZA. LONZA shall manufacture, package, store, ship, handle quality assurance and quality
control for the Product, all as set forth in the Statement of Work and the Quality Agreements, and to deliver to CLIENT the Product stated in the Statement of Work, all in accordance with the terms set forth in Section 4.7 below. Lonza and
CLIENT agree to adhere to production schedules mutually agreed upon in the relevant Statement of Work. LONZA will use commercially reasonable efforts to deliver according to such production schedules and will consult in advance and in good faith
with CLIENT regarding any amendment or change to the production schedule or the Commencement Date with respect to a Statement of Work. 

4.4 Procurement of Material. LONZA shall ensure that Materials other than CLIENT Production Materials
(hereinafter “LONZA Production Materials”) meet the requirements set forth in the relevant Project Documentation. LONZA shall, and shall cause its Affiliates and approved Third Party subcontractors to, at its/their own cost,
purchase, qualify, test, and inspect all such LONZA Production Materials. LONZA shall (i) apply first-expiry, first out methods of usage to any stock of Materials, (ii) keep CLIENT informed of the material terms and status of the Materials
supply, (iii) ensure that critical Materials as determined by CLIENT are only supplied from suppliers approved in writing by CLIENT, and (iv) keep CLIENT informed without delay of any possible interruptions with respect to the Materials
supply as soon as LONZA becomes aware of any possibility of such interruption. 

  
 9 

 4.5 Cancellation of a Statement of Work. Any Statement of Work
may be cancelled by either Party based on a material breach by the other Party of such Statement of Work, or by CLIENT in the event that LONZA fails to produce and deliver Product in compliance with the Product Warranties [***]. Each
Statement of Work shall provide for cancellation fees for such Statement of Work (the “Cancellation Fee”); provided, however, that, if such Statement of Work does not provide for cancellation fees, the Cancellation Fee shall be the
remaining amount outstanding under such Statement of Work if such Statement of Work is cancelled by CLIENT due to reasons not attributable to LONZA, but except for reasons beyond CLIENT’s control (such as a Force Majeure Event); provided,
further, that, as soon as possible but no later than [***] days after such cancellation, LONZA shall use commercially reasonable efforts to reallocate the relevant Materials, labor resources, suite, equipment and any other resources under
such Statement of Work and provide to CLIENT a good faith calculation of the total value of such reallocated Materials, labor resources, suite, equipment and any other resources within [***] days after such cancellation, and the Cancellation
Fee shall be reduced by an amount equal to such total value. 
 4.6 Payment of Cancellation Fee.[***].
 
 4.7 Packaging and Shipping. LONZA shall package and label the Product for shipment in
accordance with the Project Documentation and LONZA’s standard practices in effect at the time of LONZA’s performance of the relevant Statement of Work. LONZA shall not be entitled to deliver partial shipments of the Product unless
expressly authorized by CLIENT in writing to do so. LONZA shall ship the Product Ex Works (INCOTERMS® 2020) the LONZA Facility through (i) a common carrier designated by
CLIENT to LONZA, or (ii) a carrier recognized and accepted by CLIENT according to LONZA’s recommendation, in each case in writing not less than [***] days prior to the applicable delivery date unless otherwise agreed to in a
Statement of Work. LONZA shall (i) arrange for shipping and insurance, and (ii) at LONZA risk and expense, obtain any export license or other official authorization and carry out all customs formalities necessary to export the Product.
CLIENT shall provide to LONZA its account number with the selected carrier (if applicable) and shall pay for the shipping costs after the delivery of the Product to the carrier in connection with each shipment of Product. Each shipment shall be
accompanied by the documentation listed in the Statement of Work or required by Ex Works (INCOTERMS® 2020). Risk and title in the Product shall pass to CLIENT upon delivery to the carrier.
LONZA will, subject to the production schedule in the applicable Statement of Work, unless it is unable to do so due to one or more Batches of Product not complying with the Product Warranties (provided that each such
non-compliance shall constitute one occasion for the purpose of determining whether there is a Supply Failure under Section 4.5), exercise commercially reasonable efforts to deliver each shipment of
Product to CLIENT on the requested delivery date for such shipment. LONZA shall promptly notify CLIENT, but in any case no later than [***] days before the delivery date, if LONZA reasonably believes that it will be unable to meet a delivery
date. In such case, any such delay to the delivery dates, whether or not accepted by CLIENT, is without prejudice to CLIENT’s rights and remedies under this Agreement and applicable laws. CLIENT shall be required to take physical possession of
a Batch of Product within [***] days after acceptance of such Batch in accordance with Section 5.2 (the “Delivery Period”), unless CLIENT requests in writing, and LONZA consents in writing, to store the Product on
CLIENT’s behalf and at CLIENT’s expense. 

  
 10 

 4.8 Genetic Alterations. LONZA is not responsible for any
genetic alterations that occur during the production of any Product, except for those genetic alterations that result from negligent or intentionally or knowingly wrongful acts or omission of LONZA and not as a result of the predisposition of any
Materials provided by CLIENT. Unless they arise from negligent or wrongful acts or omissions of LONZA, genetic alterations shall not be the basis for a breach of warranty claim by CLIENT. If LONZA fails to deliver the Product in accordance with the
terms of this Agreement or a Statement of Work, or if the Product produced pursuant to the Statement of Work fails to meet any Specifications required by the Statement of Work, and such failure is due to genetic alterations which do not arise from a
negligent or wrongful act or omission of LONZA, LONZA shall re-perform the specific project at issue at the earliest practicable time, for an additional fee equal to the original fee for that part of the project. 

4.9 Records. LONZA shall maintain true, complete and accurate written records for the production of the Product
and all activities related to the Process, as required by applicable laws, regulations and industry standards. In no event shall LONZA transfer or dispose of any of the foregoing records kept or generated by LONZA without the prior written consent
from CLIENT. LONZA shall retain possession of the Project Documentation, all Batch Records and LONZA Operating Documents, and shall make copies thereof available to CLIENT upon CLIENT’s request and at CLIENT’s expense. LONZA Operating
Documents shall remain Confidential Information of LONZA. CLIENT shall have the right to use and reference any of the foregoing in connection with a filing for Regulatory Approval of the Product or as otherwise authorized by the Agreement with no
consideration. 
 4.10 CLIENT Access. 

4.10.1 CLIENT’s employees and agents (including its independent contractors) (collectively, “CLIENT
Personnel”) may participate in the production of the Product only in such capacities as may be approved in writing in advance by LONZA. CLIENT Personnel working at the Facility are required to comply with LONZA Operating Documents and any
other applicable LONZA safety policies. For the avoidance of doubt, CLIENT Personnel may not physically participate in the production or manufacture of any Product that may be used in or on humans. 

4.10.2 CLIENT Personnel working at the Facility shall be and remain employees or agents (as applicable) of CLIENT, and
CLIENT shall be solely responsible for the payment of compensation for such CLIENT Personnel (including applicable federal, state and local withholding and other payroll taxes, workers’ compensation insurance, health insurance, and other
similar statutory benefits). 
 4.10.3 CLIENT shall pay for the actual cost of repairing or replacing to its previous
status (to the extent that LONZA determines, in its reasonable judgment, that repairs cannot be adequately effected, and to the extent not exceeding the greater of the applicable market price or LONZA’s book value) any property of LONZA damaged
or destroyed by CLIENT Personnel, provided CLIENT shall not be liable for repair or replacement costs resulting from ordinary wear and tear or instructions from LONZA.  

  
 11 

 4.10.4 CLIENT Personnel visiting or having access to the Facility
shall abide by LONZA standard policies, SOPs and the security procedures established by LONZA. CLIENT shall be liable for any breaches of security by CLIENT Personnel. In addition, CLIENT shall reimburse LONZA for the cost of any lost security cards
issued to CLIENT Personnel, at the rate of $[***] per security card. All CLIENT Personnel shall agree to abide by applicable LONZA policies and SOPs established by LONZA, and will sign an appropriate confidentiality agreement in a form
reasonably acceptable to CLIENT. 
 4.10.5 CLIENT shall indemnify and hold harmless LONZA from and against any and all
Losses arising out of any injuries suffered by CLIENT Personnel while at the Facility or elsewhere, except to the extent caused by the negligence or misconduct on the part of, or instruction from, any LONZA Party. 

4.11 Disclaimers. CLIENT acknowledges and agrees that LONZA shall not engage in any Product refinement or
development. CLIENT acknowledges and agrees that LONZA has not participated in the invention or testing of any Product, and has not evaluated its safety or suitability for use in humans or otherwise. 

 

	5.	 PRODUCT WARRANTIES; ACCEPTANCE AND
REJECTION OF PRODUCTS 

 5.1 Product
Warranties. LONZA warrants that any Product manufactured by LONZA pursuant to this Agreement, at the time of delivery pursuant to Section 4.7: [***] LONZA further warrants that any Product manufactured by LONZA pursuant to this Agreement,
at the time of delivery pursuant to Section 4.7, will be free from any Third Party security interest, claims, demands, liens or other encumbrances of any kind or character. 

  
 12 

 5.2 Approval of Completed Product. 

5.2.1[***]. 

5.2.2 If Product is deemed accepted in accordance with Section 5.2.1, then, the Product shall, within [***]
days of such acceptance, be delivered to CLIENT, and CLIENT shall either (i) accept delivery at the common carrier in accordance with Section 4.7, or (ii) arrange for storage of the Product by LONZA for CLIENT in accordance with
agreed upon terms of a SOW which covers all relevant details of a Product storage engagement. 
 5.3 Dispute
Resolution. LONZA and CLIENT shall attempt to resolve any dispute regarding the conformity of a cGMP Batch with the Product Warranties. If such dispute cannot be settled within [***] days of the notice by either Party of such dispute to
the other Party, then CLIENT may submit a sample of the cGMP Batch of the disputed Product to an independent expert or independent testing laboratory of recognized repute selected by CLIENT and approved by LONZA (such approval not to be unreasonably
withheld or delayed) for analysis, under quality assurance procedures in accordance with the Quality Agreement, of the conformity of such cGMP Batch with the relevant Product Warranties. The costs associated with such analysis by such independent
expert or independent testing laboratory (as applicable) shall be paid by the Party whose assessment of the conformity of the cGMP Batch with the Product Warranties was mistaken.

5.4 Remedies for Non-Conforming, Damaged, or Destroyed Product. 

5.4.1 In the event that the Parties agree, or independent expert or independent testing laboratory (as applicable)
determines, pursuant to Section 5.3, that a cGMP Batch, Product or Material (i) is destroyed or damaged by LONZA, LONZA Personnel or a Third Party subcontractor appointed by LONZA due to a negligent or intentional act or omission by any of
said parties, or (ii) fails to conform to the Product Warranties in any material respect due to the failure of LONZA, LONZA Personnel or a Third Party subcontractor appointed by LONZA to execute the Project Documentation or to comply with cGMP,
the Quality Agreement, then, at CLIENT’s request, LONZA shall, as soon as it is commercially practicable to do so, produce for CLIENT sufficient quantities of Product to replace the non-conforming,
damaged or destroyed portion of such cGMP Batch (the “Production Rerun”), in accordance with the provisions of this Agreement and at no additional cost to CLIENT; provided, however, CLIENT shall have first paid for the original cGMP
Batch. If a replacement Product cannot be provided to CLIENT, then LONZA shall refund the cost of the original Batch of Product if CLIENT has paid for the original Batch of Product. 

  
 13 

 5.4.2 In the event that the Parties agree, or an independent testing
laboratory determines, pursuant to Section 5.3, that a cGMP Batch materially fails to conform to the Product Warranties, or Product and/or Materials are destroyed or damaged by LONZA Personnel, for any reason other than as set forth in
Section 5.4.1, then LONZA shall have no liability to CLIENT with respect to such cGMP Batch, Product or Material and LONZA will, at CLIENT’s request, produce for CLIENT a Production Rerun at CLIENT’s expense. Notwithstanding anything
to the contrary set forth in Section 5.4, if during the manufacture of Product pursuant to this Agreement, Product or Materials are destroyed or damaged by LONZA Personnel while LONZA Personnel were acting at the direction of CLIENT Personnel,
then LONZA will have no liability to CLIENT as the result of such destruction or damage. 
 5.4.3 Notwithstanding
anything to the contrary herein, in case CLIENT discovers during the registered shelf life of a Product any non-conformity of such Product with the Product Warranties, which
non-conformity was not reasonably detectable by visual inspection, CLIENT shall have the right to deliver a Disapproval Notice to LONZA in accordance with Section 5.2 within [***] days following
its discovery of such non-conformity. 
 5.4.4 CLIENT acknowledges and agrees
that its sole remedy with respect to (i) the failure of Product to conform with any of the Product Warranties and (ii) damaged or destroyed Materials and/or Product, except in the event that such damage or destruction is due to an
intentional act or omission of LONZA Personnel or a Third Party subcontractor appointed by LONZA, is as set forth in this Section 5.4, and in furtherance thereof, CLIENT hereby waives all other remedies at law or in equity regarding the
foregoing claims. 
 5.5 Product Recall and Return 

5.5.1 Recall. Each Party shall notify the other Party as soon as possible when they receive information, whether
directly or indirectly, which might affect the marketability, quality, safety or effectiveness of the Product and/or which might result in the Recall or seizure of the Product. For purposes of this Agreement, a “Recall” shall mean
any action: (i) by CLIENT to recover title to or possession of quantities of the Product sold or shipped to Third Parties (including without limitation, the voluntary withdrawal of the Product from the market), (ii) by any governmental
authorities to detain or destroy any of the Product, or (iii) the election by CLIENT to refrain from selling or shipping quantities of the Product to Third Parties that would have been subject to a Recall if sold or shipped. Each Party shall
maintain records as may be necessary to permit a Recall of the Product. CLIENT shall have the sole right to institute a Recall or field alert of the Product as a consequence of any defect that CLIENT deems sufficiently serious. 

5.5.2 Liability. For all Recalls which result from a non-conformity of a
Product with the Product Warranties, LONZA shall: (i) promptly credit CLIENT’s account for LONZA invoice price to CLIENT of such recalled Product; if CLIENT has previously paid for such Product, LONZA shall promptly, at CLIENT’s
election, either (a) refund the invoice price, (b) offset the amount thereof against other amounts then due to LONZA hereunder, or (c) replace the recalled Product with new Product at no additional cost to CLIENT; and
(ii) reimburse CLIENT for all reasonable documented out-of-pocket costs and expenses incurred by CLIENT resulting from such Recall. 

  
 14 

	6.	 FORECASTS 

6.1 CLIENT shall supply LONZA with a written forecast showing CLIENT’s good faith estimated requirements for
Batches for the following period (the “Forecast”). Applicable Forecasts will be defined in the relevant manufacturing SOWs and agreed upon in a manner that is suitable for the Product. Following LONZA’s receipt of a Forecast,
LONZA shall provide written notice to CLIENT of whether that it has capacity available to manufacture the number of Batches forecasted therein and shall provide CLIENT with an estimated production schedule showing the estimated Commencement Date and
estimated delivery date of each Batch. Notwithstanding the forgoing, during the term of this Agreement, LONZA shall maintain a monthly minimum capacity for the manufacturing of [***] percent ([***]%) of the applicable Forecast
(“Minimum Capacity”). LONZA shall use commercially reasonable efforts to increase its capacity up to the required quantity of Product within a reasonable time if CLIENT requires a higher minimum capacity at any time during this
Agreement, provided LONZA’s failure to achieve an increased level of capacity that is in excess of [***] percent ([***]%) of the then-applicable Forecast shall not constitute a material breach of this Agreement. 

 

	7.	 STORAGE OF MATERIALS 

7.1 Pre-Production. LONZA shall store at the expense of CLIENT any CLIENT
Materials, equipment or other property delivered pursuant to the Statement of Work to the Facility by CLIENT more than [***] days prior to the Commencement Date. The storage rates shall be set forth in the Statement of Work and may be amended
from time to time by written consent of the Parties. No storage fees shall be charged during the period starting [***] days prior to the Commencement Date and ending upon completion of the manufacturing of the applicable Product. 

7.2 Post-Production. LONZA shall store at the Facility free of charge, or dispose of in accordance with
CLIENT’s instruction and at CLIENT’s expense, any in–process Materials, CLIENT Materials, equipment and other CLIENT property that remains at the Facility on the date of completion of the manufacturing of the applicable Product or the
termination of this Agreement (collectively “Remaining CLIENT Property”), for up to [***] days. If CLIENT has not provided any instructions as to the shipment or other disposition of Remaining CLIENT Property
prior to the expiration of such [***]-day period, LONZA shall notify CLIENT in writing and continue to store such Remaining CLIENT Property at the Facility, and CLIENT shall pay to LONZA a storage charge at LONZA’s then-standard monthly
storage rates for the period beginning on the [***] day after the completion of the manufacturing of the applicable Product through the date that such storage terminates. 

7.3 Product. Notwithstanding the foregoing, if CLIENT fails to take delivery of a Product within the applicable
Delivery Period as required by Section 4.7, CLIENT shall pay to LONZA a storage charge at LONZA’s then-standard monthly storage rate, which shall begin accruing on the first day following the expiration of the applicable Delivery Period.

  
 15 

	8.	 REGULATORY MATTERS 

8.1 Permits and Approvals. During the term of this Agreement, LONZA shall use best efforts to maintain, and cause
its Affiliates to maintain, and use commercially reasonable efforts to cause its approved Third Party subcontractors to maintain, all licenses, permits and approvals necessary for the manufacture of the Product in the Facility. LONZA shall promptly
notify CLIENT in writing if LONZA, its Affiliate or any approved Third Party subcontractor receives notice that any such license, permit, or approval is or may be revoked, suspended, withdrawn or otherwise under investigation. 

8.2 Inspections/Quality Audit by CLIENT. 

8.2.1 Except as otherwise set forth in the Quality Agreements, up to once per year and upon not less than [***]
days’ prior written notice, LONZA shall permit CLIENT and its representative to inspect and audit the parts of the Facility where the manufacture of the Product is carried out in order to inspect the CLIENT Materials, assess LONZA’s
compliance with cGMP and applicable laws, and to discuss any related issues with LONZA’s management and technical personnel. LONZA shall make all applicable records maintained in accordance with Section 4.9 available for such inspection
and audit. Such audit shall not last for more than [***] business days. CLIENT Personnel engaged in such inspection shall abide by the terms and conditions set forth in Section 4.10.4 and Article 10. Each Party shall bear its own
expenses with respect to any audit and inspection pursuant to this Section 8.2. 
 8.2.2 In addition to the
foregoing, CLIENT and/or its representatives shall have the right to perform “For Cause” audits at any time upon reasonable advance notice and during regular business hours. If a For Cause audit confirms that LONZA did not comply with its
obligations under the Agreement, the audit shall not be charged by LONZA and LONZA shall bear its costs for such audit; in all other cases LONZA’s standard hourly rates apply; provided that such rates shall not exceed industry standards for
CDMO (Contract Development Manufacture Organization) hourly rates and have been notified to CLIENT in advance. Notwithstanding the foregoing, a For Cause audit shall also be at no cost for CLIENT if it is CLIENT’s sole audit in such calendar
year. For the avoidance of doubt, any and all costs related to deviations and or modifications to the Facility requested and/or approved by CLIENT (outside of those related to GMP violations attributable to LONZA which costs shall be the sole
responsibility of LONZA) related to the manufacturing of Products will be charged on an hourly basis according to LONZA’s standard hourly rates (which shall not exceed industry standards for CDMO hourly rates and have been notified to CLIENT in
advance) and invoiced monthly.  
 8.2.3 Inspections by Regulatory Agencies. LONZA shall allow
representatives of any regulatory agency to inspect the relevant parts of the Facility where the manufacture of the Product is carried out and to inspect the Project Documentation and Batch Records to verify compliance with cGMP and other practices
or regulations and shall promptly notify CLIENT of the scheduling of any such inspection which could impact the manufacture of Product. LONZA shall promptly (within [***] days) send to CLIENT a copy of any reports, citations, or warning
letters received by LONZA in connection with an inspection by a regulatory agency to the extent such documents relate to or affect the manufacture of the Product. 

  
 16 

	9.	 FINANCIAL TERMS 

9.1 Payments. CLIENT shall make payments to LONZA in the amounts and on the dates set forth in the Statement of
Work after receipt of the relevant invoice from LONZA. In the event that CLIENT has not paid an invoice within [***] business days of the applicable due date (as established by Section 9.2), and fails to pay such amount within
[***] days following its receipt of a written late payment notice from LONZA, CLIENT’s failure shall be considered a material breach under Section 14.2, subject to the cure provisions set forth therein. Further, in
addition to all other remedies available to LONZA, in the event that CLIENT has not paid an invoice within [***] business days of the applicable due date (as established by Section 9.2), LONZA may elect to suspend the provision of all or
a portion of the Services under this Agreement, provided that CLIENT shall remain liable for all fees owed for the Services provided or Product delivered pursuant to the Statement of Work during any such suspension.  

9.2 Invoices and Pricing. LONZA shall charge for the Services in accordance with the price schedule in the
relevant Statement of Work. LONZA shall invoice CLIENT according to the schedule set forth in the relevant Statement of Work. LONZA shall deliver invoices electronically by email, which shall be considered to be an original invoice. Invoices should
be e-mailed to [***], and/or to such other e-mail address(es) as CLIENT may stipulate from time to time. LONZA shall not deliver a paper invoice. Payment of
invoices is due as provided in the Statement of Work. Unless otherwise provided in the Statement of Work, all pricing excludes taxes and costs relating to shipping, validation and regulatory filings. The price shall be invoiced to CLIENT in U.S.
Dollars.  
 9.3 Taxes. CLIENT agrees that it is responsible for and shall pay any sales,
value-added or other taxes (the “Taxes”) imposed on CLIENT by applicable laws and resulting from LONZA’s production of Product under this Agreement (which, for the avoidance of doubt, shall not include income or personal
property taxes, or other taxes imposed on LONZA by applicable laws). CLIENT will indemnify and hold harmless the LONZA Parties from and against any and all penalties and reasonable fees, expenses and costs incurred by LONZA due to the failure by
CLIENT to pay such Taxes. LONZA will not collect any sales or value-added taxes from CLIENT in connection with the production of any Product or provision of Services hereunder if CLIENT provides to LONZA the appropriate valid exemption certificates.

 9.4 Interest. Any fee, charge or other payment due to LONZA by CLIENT under this Agreement that is not paid
within [***] business days after it is due will accrue interest on a daily basis at a rate of [***] percent ([***]%) per month (or the maximum interest rate allowed by applicable laws, if less) from and after such date. 

  
 17 

 9.5 Method of Payment. Except as otherwise set forth in
Section 9.2, all payments to LONZA hereunder by CLIENT shall be in U.S. Dollars and shall be by check, wire transfer, money order, or other method of payment approved by LONZA. Bank information for wire transfers is as follows: 

Mailing address for wire transfer payments: 

                        
To: 

                        
Branch: 

                        
Account Number: 

                        
ABA# (for Wires): 

                        
ABA# (for EFTS): 

                        
Swift#: 

                       
 Please email remittance advice to [***]. 
 9.6 Cost Adjustments. After the first (1st) anniversary of the Effective Date, LONZA may, with prior consultation in good faith with CLIENT, annually adjust the various costs and rates set forth in the Statement of Work attached hereto to
reflect changes in the cost of Materials and/or labor rates paid by LONZA in connection with the production of the Product under this Agreement; provided, however, that any increase in cost and rates shall not exceed any percentage increase in the
U.S. Consumer Price Index as determined by the U.S. Central Bureau for Statistics on their website for the most recently published percentage change for the [***]-month period preceding the applicable contract anniversary date and
(ii) the cost of Materials shall not exceed the applicable market price at the applicable contract anniversary date. In addition to the foregoing, the price may be changed by LONZA, with prior notification to CLIENT, to reflect any material
change in an environmental or regulatory standard that substantially impacts LONZA’s cost and ability to manufacture the Product subject to Lonza using commercially reasonable efforts to minimize the impact to CLIENT. 

 

	10.	 CONFIDENTIAL INFORMATION 

10.1 Definition. “Confidential Information” means all technical, scientific and other know-how and information, trade secrets, Intellectual Property, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, specifications, data, results and
other material, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, and any tangible embodiments of any of the foregoing, and any
scientific, manufacturing, marketing and business plans, operations, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees, investors or business, regardless of form or
medium (e.g. electronic, magnetic, oral, written, information obtained through observation at a Party’s facility), that has been disclosed by or on behalf of such Party or such Party’s Affiliates to the other Party or the other
Party’s Affiliates either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement. Without limiting the foregoing, the terms of this Agreement will be deemed
“Confidential Information” and will be subject to the terms and conditions set forth in this Article 10. 

  
 18 

 10.2 Exclusions. Notwithstanding the foregoing
Section 10.1, any information disclosed by a Party to the other Party will not be deemed “Confidential Information” to the extent that such information: 

(a) at the time of disclosure is in the public domain; 

(b) becomes part of the public domain, by publication or otherwise, through no fault of the Party receiving such information;

 (c) at the time of disclosure is already in possession of the Party who received such information, as established by
contemporaneous written records; 
 (d) is lawfully provided to a Party, without restriction as to confidentiality or use,
by a Third Party lawfully entitled to possession of such Confidential Information; or 
 (e) is independently developed by a
Party without use of or reference to the other Party’s Confidential Information, as established by contemporaneous written records. 

10.3 Disclosure and Use Restriction. Except as expressly provided herein, the Parties agree that this Article 10
will survive any expiration or termination of this Agreement, each Party and its Affiliates will keep completely confidential and will not publish or otherwise disclose any Confidential Information of the other Party, its Affiliates or approved
Third Party subcontractor, except in accordance with Section 10.4. Neither Party will use, disclose, publish or otherwise share with Third Parties Confidential Information of the other Party except as necessary to perform its obligations or to
exercise its rights under this Agreement. 
 10.4 Permitted Disclosures. Each receiving Party agrees to
(i) institute and maintain security procedures to identify and account for all copies of Confidential Information of the disclosing Party and (ii) limit disclosure of the disclosing Party’s Confidential Information to its Affiliates
and each of its and their respective officers, directors, employees, agents, consultants and independent contractors having a need to know such Confidential Information for purposes of this Agreement; provided that such Affiliates and each of its
and their respective officers, directors, employees, agents, consultants and independent contractors are informed of the terms of this Agreement and are subject to obligations of confidentiality,
non-disclosure and non-use similar to those set forth herein. 

10.5 Government-Required Disclosure. If a duly constituted government authority, court or regulatory agency
orders that a Party hereto disclose any Confidential Information, such Party shall comply with such order, but shall notify the other Party as soon as possible, so as to provide the other Party an opportunity to apply to a court of record for relief
from such order. 

  
 19 

 10.6 Publicity. Neither Party shall refer to, display or use
the other’s name, trademarks or trade names confusingly similar thereto, alone or in conjunction with any other words or names, in any manner or connection whatsoever, including any publication, article, or any form of advertising or publicity,
except with the prior written consent of the other Party or as otherwise set forth in Section 10.7. 
 10.7
Publications. The confidentiality provisions of this Article 10 are applicable to all publications, abstracts, and papers authored by LONZA, or its employees, consultants or contractors relating to the Services performed by LONZA hereunder or
to data created pursuant to or related to the Statement of Work; provided that no Confidential Information may be disclosed in such publications, abstracts or papers without the prior written consent of CLIENT. Manuscripts of all such publications
shall be submitted to CLIENT at least [***] days prior to submission to any publisher. CLIENT shall promptly inform LONZA of any alterations or deletions necessary to protect its rights under this Article 10 and LONZA shall be obligated to
make such changes prior to submitting any manuscripts to any publisher. For general business development purposes, LONZA may announce on its website or in press releases the general nature of work performed for CLIENT under any given Statement of
Work upon receiving prior written permission from CLIENT, such permission not being unreasonably withheld or delayed. 
  

	11.	 INTELLECTUAL PROPERTY 

11.1 Ownership. 

11.1.1 Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any
right or title to, or interest in, any Background Intellectual Property of the other Party. Except as expressly otherwise provided herein, nothing in this Agreement shall constitute or grant any implied license or ownership in proprietary rights or
permission to file any patent, copyright or any other rights to either Party under the other Party’s Background Intellectual Property or any improvements, derivatives, or developments of the other Party’s Background Intellectual Property.
For the avoidance of doubt, CLIENT is the sole and exclusive owner of CLIENT FasTCAR Technology, notwithstanding the Technology Transfer. 

11.1.2 The Parties agree and acknowledge that LONZA will not perform any Process or Product development work and
therefore no new Intellectual Property belonging to any LONZA Party will be created under this Agreement. In the event CLIENT requests any Process or Product development work to be carried out by LONZA, then the Parties shall negotiate in good faith
to determine the Parties’ respective rights regarding any Intellectual Property created in connection with such Process or Product development work. 

11.2 License Grants. 

11.2.1 During the term of this Agreement, CLIENT hereby grants to LONZA a fully paid,
non-exclusive, non-transferable and non-sublicensable license under any and all CLIENT Intellectual Property for the sole and
limited purpose of LONZA’s performance of its obligations under this Agreement, including, without limitation, the development of the Process and the manufacture of Product for CLIENT, provided that LONZA’s use of such license grant is
subject to and in accordance with the disclosure and use restrictions as set forth in Section 10.3. 

  
 20 

 11.2.2 Subject to the terms and conditions set forth herein
(including the payment required under this Agreement), LONZA hereby grants to CLIENT a non-exclusive, world-wide, fully paid-up, irrevocable and transferable license,
including the right to grant sublicenses, under the Intellectual Property of LONZA, to use, sell, process, integrate, combine, export and import the Product manufactured under this Agreement, to the extent necessary for CLIENT to fulfill its
obligations and exercise its rights under this Agreement. 
 11.3 Third Party Intellectual Property. LONZA
shall not, and shall cause its Affiliates, Third Parties subcontractors and agents and their respective personnel involved in the performance of this Agreement not to, necessarily incorporate into the Product or Process in the performance of its
obligations under this Agreement or any Statement of Work, any technology, information, know-how, trade secret or materials of a Third Party except for which LONZA is freely permitted to utilize without
compensation or other obligation to any Third Party. 
 11.4 Further Assurances. Each Party agrees to take all
necessary and proper acts, and will cause its employees, Affiliates, contractors, and consultants to take such necessary and proper acts, to effectuate the ownership provisions set forth in this Article 11. 

11.5 Prosecution of Patents. CLIENT shall have the sole right and discretion to file, prosecute and maintain
patent applications and patents claiming any new Intellectual Property of CLIENT at CLIENT’s expense. LONZA shall use commercially reasonable efforts to cooperate with CLIENT to file, prosecute and maintain patent applications and patents
claiming such new Intellectual Property of CLIENT. 
 11.6 IP Infringement. If LONZA becomes aware of any
infringement of CLIENT or its Affiliates’ Intellectual Property relating to the Product or Processes, LONZA shall use commercially reasonable efforts to promptly notify CLIENT in writing thereof. For clarity, LONZA shall have no affirmative
obligation to monitor for any such infringement nor any obligation to perform investigations regarding said infringement or any other obligation beyond those made express in this Section 11.6. CLIENT acknowledges that LONZA is not responsible
for monitoring CLIENT or its Affiliates’ Intellectual Property or the infringement thereof by Third Parties and that LONZA will not be monitoring as such. 
  

	12.	 REPRESENTATIONS AND WARRANTIES 

12.1 By CLIENT. CLIENT hereby represents and warrants to LONZA that, 

12.1.1 (i) it has the requisite Intellectual Property and legal rights related to the CLIENT Materials and the Product
to authorize the performance of LONZA’s obligations under this Agreement, and (ii) to the best of its knowledge, the performance of the Statement of Work and the production by LONZA of the Product as contemplated in this Agreement will not
give rise to a cause of action by a Third Party against LONZA for infringement or another violation of Intellectual Property rights by the CLIENT Materials; provided, that such representation and warranty will not apply to any equipment or
production materials supplied by LONZA, and 

  
 21 

 12.1.2 it has the corporate power, authority and the legal right to
enter into this Agreement and to perform its obligations under this Agreement; this Agreement has been duly executed and delivered on behalf of CLIENT, and constitutes a legal, valid and binding obligation, enforceable against CLIENT in accordance
with its terms except that the enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles;
the execution, delivery and performance of this Agreement does not breach, violate, contravene or constitute a default under any contracts, arrangements or commitments to which CLIENT is a party or by which it is bound nor does the execution,
delivery and performance of this Agreement by CLIENT violate any order, law or regulation of any court, governmental body or administrative or other agency having authority over it. 

12.2 By LONZA. LONZA hereby represents and warrants to CLIENT that, 

12.2.1 it or its Affiliates have the requisite Intellectual Property rights in Intellectual Properties of LONZA, LONZA
Confidential Information, and its equipment and Facility to be able to perform its obligations under this Agreement and the Statements of Work; 

12.2.2 to the best of its knowledge, LONZA’s or its Affiliates’ use of its equipment and Facility as
contemplated in this Agreement and the Statements of Work will not give rise to a potential cause of action by a Third Party against CLIENT for infringement or violation of Intellectual Property rights; and as of the Effective Date, no Third Party
has filed, pursued or maintained or threatened in writing to file, pursue or maintain any claim, lawsuit, charge, complaint or other action alleging infringement of the Intellectual Property of a Third-Party based on the Intellectual Property of
LONZA that will be used in connection with this Agreement; 
 12.2.3 it or its Affiliate holds all necessary permits,
approvals, consents and licenses to enable it to perform the Services at the Facility; 
 12.2.4 it owns or lawfully
controls the Facility; 
 12.2.5 it has the corporate power, authority and the legal right to enter into this
Agreement and the Quality Agreement and to perform its obligations under this Agreement and the Quality Agreement; this Agreement has been duly executed and delivered on behalf of LONZA, and constitutes a legal, valid and binding obligation,
enforceable against LONZA in accordance with its terms except that the enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights
generally and by general equitable principles; the execution, delivery and performance of this Agreement does not breach, violate, contravene or constitute a default under any contracts, arrangements or commitments to which LONZA is a party or by
which it is bound nor does the execution, delivery and performance of this Agreement by LONZA violate any order, law or regulation of any court, governmental body or administrative or other agency having authority over it; and 

  
 22 

 12.2.6 neither LONZA or its Affiliates nor any of its or their
employees or Third Party subcontractors have been “debarred” by the FDA, or subject to a similar sanction from another regulatory authority, nor have, to LONZA’s best knowledge, any debarment proceedings against LONZA, its Affiliates
or any of its or their employees or Third Party subcontractors been commenced. 
  

	13.	 DISCLAIMER; LIMITATION OF LIABILITY

 13.1 DISCLAIMER. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, NEITHER PARTY
MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, UNDER THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, LONZA SPECIFICALLY DISCLAIMS ANY AND ALL
WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE WITH RESPECT TO THE PRODUCTS, MATERIALS, OR SERVICES PROVIDED UNDER THIS AGREEMENT. 

13.2 DISCLAIMER OF CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR
ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH THIS AGREEMENT, EVEN IF
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 13.3 LIMITATION OF LIABILITY. BOTH PARTIES HEREBY AGREE THAT TO THE
FULLEST EXTENT PERMITTED BY LAW, EACH PARTY’S LIABILITY TO THE OTHER PARTY, FOR ANY AND ALL INJURIES, CLAIMS, LOSSES, EXPENSES, OR DAMAGES, WHATSOEVER, ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT FROM ANY CAUSE OR CAUSES, INCLUDING,
BUT NOT LIMITED TO, NEGLIGENCE, ERRORS, OMISSIONS OR STRICT LIABILITY, SHALL NOT EXCEED THE TOTAL CONSIDERATION PAID UNDER THE APPLICABLE STATEMENT OF WORK. TO THE EXTENT THAT THIS CLAUSE CONFLICTS WITH ANY OTHER CLAUSE, THIS CLAUSE SHALL TAKE
PRECEDENCE OVER SUCH CONFLICTING CLAUSE. IF APPLICABLE LAW PREVENTS ENFORCEMENT OF THIS CLAUSE, THEN THIS CLAUSE SHALL BE DEEMED MODIFIED TO PROVIDE THE MAXIMUM PROTECTION FOR THE RELEVANT PARTY AS IS ALLOWABLE UNDER THE APPLICABLE LAW.
NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN, THIS LIMITATION OF LIABILITY SHALL NOT EXTEND TO DAMAGES CAUSED BY A GROSSLY NEGLIGENT OR WILFUL VIOLATION OF ARTICLES 10 (CONFIDENTIAL INFORMATION) OR 11 (INTELLECTUAL PROPERTY) OR TO
CLIENT’S INDEMNITY LIABILITY UNDER SECTION 15.2(a), (c), and (d). 

  
 23 

	14.	 TERM AND TERMINATION 

14.1 Term. The term of this Agreement will commence on the Effective Date and will continue until the fifth (5th) anniversary of the Effective Date unless terminated prior to that time or extended by the Parties. 

14.2 Termination for Material Breach. Either Party may terminate this Agreement, by written notice to the other
Party, for any material breach of this Agreement by the other Party, if such breach is not cured within [***] days after the breaching Party receives written notice of such breach from the non-breaching
Party; provided, however, that if such breach is not capable of being cured within such [***]-day period and the breaching Party has commenced and diligently continued actions to cure such breach within such [***]-day period, except in
the case of a payment default, the cure period shall be extended to [***] days, so long as the breaching Party is making diligent efforts to cure such default. Such termination shall be effective upon expiration of such cure period. 

14.3 Other Termination by CLIENT. 

14.3.1 CLIENT may terminate this Agreement by [***] days written notice to LONZA, in the event of a Supply
Failure by LONZA. 
 14.3.2 After the first anniversary of the Effective Date, CLIENT may terminate this Agreement by
providing a written notice of termination no less than twelve months in advance of the date of termination. 
 14.4
Termination for Insolvency. Either Party may terminate this Agreement upon notice to the other Party, upon (a) the dissolution, termination of existence, liquidation or business failure of the other Party; (b) the appointment of a
custodian or receiver for the other Party who has not been terminated or dismissed within [***] days of such appointment; (c) the institution by the other Party of any proceeding under national, federal or state bankruptcy,
reorganization, receivership or other similar laws affecting the rights of creditors generally or the making by such Party of a composition or any assignment for the benefit of creditors under any national, federal or state bankruptcy,
reorganization, receivership or other similar laws affecting the rights of creditors generally, which proceeding is not dismissed within [***] days of filing. All rights and licenses granted pursuant to this Agreement are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code, licenses of rights of “intellectual property” as defined therein. 

  
 24 

 14.5 Effects of Termination. 

 

	14.5.1	 Accrued Rights. Termination of this Agreement for any reason will be without prejudice to any
rights that will have accrued to the benefit of a Party prior to such termination. Such termination will not relieve a Party of obligations that are expressly indicated to survive the termination of this Agreement. Without limitation of the
foregoing, in the event of termination hereunder other than termination by CLIENT under Section 14.2 or 14.3.1, LONZA shall be compensated for (i) Services rendered up to the date of termination, including in respect of any Product in-process; (ii) all reasonable and adequately documented costs incurred or non-cancellable commitments through the date of termination, including costs and fees for
Materials used or purchased for use in connection with the Services; and (iii) except in the case of termination by CLIENT under Section 14.2, 14.3.1 or 14.4, any applicable Cancellation Fees. In the case of termination by LONZA for
CLIENT’s material breach, all scheduled Services and Batches shall be deemed cancelled by CLIENT, and Cancellation Fees, if any, shall be calculated as of the date of written notice of termination. In the case of termination by CLIENT for
LONZA’s material breach, a Supply Failure or LONZA’s insolvency, LONZA shall use commercially reasonable efforts to support and finance the transfer of the manufacturing of the Products to a new and competent manufacturer which shall be
appointed at the sole discretion of CLIENT and is capable of carrying out the activities defined in the relevant SOWs, provided that LONZA’s support, financing, and total liability under this Section 14.5.1 shall not exceed [***]
USD (US$[***]). 

 14.5.2 Disposition of Remaining CLIENT Property and
Confidential Information. Upon termination or expiration of this Agreement, LONZA shall (i) store, or dispose of in accordance with CLIENT’s instruction and at CLIENT’s expense, any Remaining CLIENT Property as set forth in
Section 7.2, and (ii) at CLIENT’s option, return or destroy any Confidential Information of CLIENT in the possession or control of LONZA. Likewise, CLIENT shall, at LONZA’s option, return or destroy any Confidential Information
of LONZA in the possession or control of CLIENT. Notwithstanding the foregoing provisions: (A) LONZA may retain and preserve, at its sole cost and expense, samples and standards of each Product following termination or expiration of this
Agreement solely for use in determining LONZA’s rights and obligations hereunder; and (B) each Party may retain a single copy of the other Party’s Confidential Information for documentation purposes only and which shall remain subject
to the obligations of nonuse and confidentiality set forth in this Agreement.
 14.5.3 Survival. Sections 3.4,
7.2, 10, 11.1, 11.2, 11.4, 11.5, 11.6, 13, 14.5, 15, 17.3, 17.5 and 17.14 of this Agreement, together with any appendices referenced therein, will survive any expiration or termination of this Agreement. 

  
 25 

	15.	 INDEMNIFICATION 

15.1 Indemnification of CLIENT. LONZA shall indemnify CLIENT, its Affiliates, and their respective directors,
officers, employees, agents, successors and assignees (the “CLIENT Parties”), and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys’ fees and expenses, collectively, “Losses”) incurred or suffered by the CLIENT Parties to the extent such Losses arise out of or result from any claim, settlements, penalties, proceeding, lawsuit, or other action or
threat by a Third Party (collectively, “Third Party Claims”) arising out of or in connection with: (a) any breach by any LONZA Party of this Agreement, the Quality Agreement or any Statement of Work, (b) any Supply Failure
by LONZA, (c) any infringement or misappropriation of CLIENT Intellectual Property or any Third Party Intellectual Property, with respect to LONZA Parties’ performance of the Services to the extent such infringement or misappropriation was
caused by a LONZA Party, or (d) the gross negligence, intentional act or omission, or misconduct on the part of one or more of the LONZA Parties in performing any activity contemplated by this Agreement or any Statement of Work, except for
those Losses for which CLIENT has an obligation to indemnify the LONZA Parties pursuant to Section 15.2, as to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses. 

15.2 Indemnification of LONZA. CLIENT will indemnify LONZA and its Affiliates, and their respective directors,
officers, employees and agents (the “LONZA Parties”), and defend and hold each of them harmless, from and against any and all Losses to the extent such Losses arise out of or result from any Third Party Claim arising out of
or in connection with: (a) any breach by CLIENT of this Agreement, the Quality Agreement or any Statement of Work, (b) the gross negligence, intentional act or omission, or misconduct on the part of CLIENT or its Affiliates in performing
any activity contemplated by this Agreement, (c) the use or sale of Products, except to the extent such Losses arise out of or result from a breach by LONZA of the Product Warranties including the Quality Agreement, or (d) the use or
practice by LONZA of any process, invention or other Intellectual Property supplied by CLIENT to LONZA under this Agreement, except for those Losses for which LONZA has an obligation to indemnify the CLIENT Parties pursuant to Section 15.1, as
to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses. 

15.3 Indemnification Procedure. 

15.3.1 The Party seeking indemnification under Section 15.1 or Section 15.2 (the
“Indemnitee”) agrees to give prompt notice in writing to the Party against whom indemnity is to be sought (the “Indemnitor”) of the assertion of any Third Party Claim in respect of which indemnity may be sought
under Section 15.1 or Section 15.2 (as applicable). Such notice shall set forth in reasonable detail such Third Party Claim and the basis for indemnification (taking into account the information then available to the Indemnitee). The
failure to so notify the Indemnitor shall not relieve the Indemnitor of its obligations hereunder, except to the extent such failure shall have materially and adversely prejudiced the Indemnitor. 

15.3.2 The Indemnitor shall be entitled to participate in the defense of any Third Party Claim and, subject to the
limitations set forth in this Section 15.3, shall be entitled to control and appoint lead counsel for such defense, in each case at its own expense. 

  
 26 

 15.3.3 The Indemnitor shall not be entitled to assume or maintain
control of the defense of any Third Party Claim and shall pay the reasonable fees and expenses of counsel retained by the Indemnitee if the Indemnitor has failed or is failing to prosecute or defend vigorously the Third Party Claim. 

15.3.4 If the Indemnitor shall assume the control of the defense of any Third Party Claim in accordance with the
provisions of this Section 15.3, the Indemnitor shall obtain the prior written consent of the Indemnitee before entering into any settlement of such Third Party Claim if the settlement does not expressly unconditionally release the Indemnitee
and its Affiliates from all liabilities and obligations with respect to such Third Party Claim or the settlement imposes injunctive or other equitable relief against the Indemnitee or any of its affiliates. 

15.3.5 In circumstances where the Indemnitor is controlling the defense of a Third Party Claim in accordance with
Section 15.3.2 and Section 15.3.3 above, the Indemnitee shall be entitled to participate in the defense of such Third Party Claim and to employ separate counsel of its choice for such purpose, in which case the fees and expenses of such
separate counsel shall be borne by the Indemnitee. 
 15.3.6 Each Party shall cooperate, and cause its Affiliates to
cooperate, in the defense or prosecution of any Third Party Claim and shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be
reasonably requested in connection therewith. 
 15.4 Insurance. Each Party shall maintain in full force and
effect, at its sole cost and expense, and at all times during the term of this Agreement, a policy of commercial general liability insurance, including product liability, with limits of not less than US$[***] in the aggregate. Each Party
shall maintain its respective insurance policies required under this Section 15.4 with an insurance company having a minimum AM Best rating of A. LONZA shall also maintain property insurance for the storage of Client Production Materials at the
LONZA Facility. LONZA will reimburse the value of any destroyed Client Production Materials to the extent of LONZA’s insurance proceeds according to policies governing such losses. 

 

	16.	 ADDITIONAL COVENANTS 

16.1 Non-Solicitation. During the term of this Agreement and for one
(1) year thereafter, each of the Parties agrees not to seek to induce or solicit any employee of the other Party or its Affiliates to discontinue his or her employment with the other Party or its Affiliate in order to become an employee of the
soliciting Party or its Affiliate; provided, however, that neither Party shall be in violation of this Section 16.1 as a result of making a general solicitation for employees. For the avoidance of doubt, the publication of an advertisement
shall not constitute solicitation or inducement. 

  
 27 

 16.2 Non-USE. LONZA
will not, will cause its Affiliates and their respective employees not to, and will use commercially reasonable efforts to cause its Third Party subcontractors and their employees not to, acquire any right or title to, or interest in, and will not
use, any Confidential Information, inventions (whether or not patentable), discoveries, improvements, data, information, reports and any and all related documentation provided by CLIENT, including but not limited to information with respect to
CLIENT’s FasTCAR Technology, to LONZA under the Agreement or a Statement of Work. 
 16.3 Covenants. LONZA
agrees that: (i) it will engage and employ only professionally qualified personnel to perform the Services; (ii) its obligations under this Agreement and the Statements of Work will be performed in professional and workmanlike manner and
in compliance with this Agreement, the Quality Agreements, and any applicable laws and industry standards; and (iii) all individuals and entities that perform any Services for or on behalf of LONZA are under written obligations to assign all
right and title to, and interest in, any Intellectual Property arising from such Services to LONZA and to protect Confidential Information of CLIENT in accordance with Article 10 of this Agreement. LONZA will promptly notify CLIENT in writing if
LONZA becomes aware that LONZA, its Affiliates or any of its or their employees or Third Party subcontractors are debarred by the FDA or any other regulatory authority, or that any debarment proceedings have commenced against any of the above
referenced entities or individuals. 
  

	17.	 MISCELLANEOUS 

17.1 Independent Contractors. Each of the Parties is an independent contractor and nothing herein contained shall
be deemed to constitute the relationship of partners, joint venturers, nor of principal and agent between the Parties. Neither Party shall at any time enter into, incur, or hold itself out to Third Parties as having the authority to enter into or
incur, on behalf of the other Party, any commitment, expense, or liability whatsoever. 
 17.2 Force Majeure.
Neither Party shall be in breach of this Agreement if there is any failure of performance under this Agreement caused by any reason beyond the control and without the fault or negligence of the Party affected thereby, including, without limitation,
an act of God, fire, flood, act of government or state, war, civil commotion, insurrection, acts of terrorism, embargo, sabotage, a viral, bacterial or mycoplasma contamination (except for effects of the
COVID-19 pandemic which occurred and were known to the affected Party before or on the Effective Date) which causes a shutdown of the Facility, prevention from or hindrance in obtaining energy or other
utilities, a shortage of raw materials or other necessary components, or any other reason beyond the control and without the fault or negligence of the Party affected thereby (a “Force Majeure Event”). Such excuse shall continue as
long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, the affected Party shall promptly resume performance under this Agreement as soon as it is commercially reasonable for the Party to do so. Each Party agrees to
give the other Party prompt written notice of the occurrence of any Force Majeure Event, the nature thereof, and the extent to which the affected Party will be unable to fully perform its obligations under this Agreement. Each Party further agrees
to use commercially reasonable efforts to correct the Force Majeure Event as quickly as practicable and to give the other Party prompt written notice when it is again able to perform such obligations. 

  
 28 

 17.3 Notices. Any notice required or permitted to be given
under this Agreement by any Party shall be in writing and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested, postage prepaid, (c) sent by a nationally-recognized courier service guaranteeing next-day or second day delivery, charges prepaid, or (d) delivered by facsimile or e-mail (with documented evidence of transmission and confirmation by another
communication method as listed above), to the e-mail addresses or facsimile numbers of the other Party set forth below, or at such other addresses as may from time to time be furnished by similar notice by any
Party. The effective date of any notice under this Agreement shall be the date of receipt by the receiving Party. 
 If to LONZA:

 [***] 
 Attn:
[***] 
 Email: [***] 

With a copy to: 
 [***]

 Fax: [***] 
 Email:
[***] 
 If to CLIENT: 

[***] 
 Attn:
[***] 
 Email: [***] 

With a copy to: 
 [***]

 Attn: [***] 
 Email:
[***] 
 Either Party may change its address for notice by giving notice thereof in the manner set forth in this Section 17.3.

 17.4 Entire Agreement; Amendments. This Agreement, including the appendices attached hereto and referenced
herein, constitutes the full understanding of the Parties and a complete and exclusive statement of the terms of their agreement with respect to the specific subject matter hereof and supersedes all prior agreements and understandings, oral and
written, among the Parties with respect to the subject matter hereof. No terms, conditions, understandings or agreements purporting to amend, modify or vary the terms of this Agreement (including any Appendix hereto) shall be binding unless
hereafter made in a written instrument referencing this Agreement and signed by each of the Parties. 

  
 29 

 17.5 Governing Law. The construction, validity and performance
of the Agreement and Statements of Work shall be governed by and construed in accordance with the laws of the US State of New York, without giving effect to its conflict of law provisions.  

17.6 Counterparts. This Agreement and any amendment hereto may be executed in any number of counterparts, each of
which shall for all purposes be deemed an original and all of which shall constitute the same instrument. This Agreement shall be effective upon full execution by facsimile or original, and a facsimile signature shall be deemed to be and shall be as
effective as an original signature. 
 17.7 Severability. If any part of this Agreement shall be found to be
invalid or unenforceable under applicable laws in any jurisdiction, such part shall be ineffective only to the extent of such invalidity or unenforceability in such jurisdiction, without in any way affecting the remaining parts of this Agreement in
that jurisdiction or the validity or enforceability of the Agreement as a whole in any other jurisdiction. In addition, the part that is ineffective shall be reformed in a mutually agreeable manner so as to as nearly approximate the intent of the
Parties as possible. 
 17.8 Titles and Subtitles. All headings, titles and subtitles used in this Agreement
(including any Appendix hereto) are for convenience only and are not to be considered in construing or interpreting any term or provision of this Agreement (or any Appendix hereto). 

17.9 Exhibits. All “RECITALS”, “DEFINITIONS”, exhibits and appendices referred to herein form
an integral part of this Agreement and are incorporated into this Agreement by such reference. 
 17.10
Pronouns. Where the context requires, (i) all pronouns used herein will be deemed to refer to the masculine, feminine or neuter gender as the context requires, and (ii) the singular context will include the plural and vice versa.

 17.11 Subcontractors. LONZA shall not subcontract or delegate any portion of its obligations under this
Agreement, any Statement or Work or the Quality Agreement to any Third Party without the prior written approval of CLIENT, such approval not to be unreasonably withheld, delayed or conditioned. In the event CLIENT consents to the use of a
subcontractor to provide any of the Services, (i) LONZA shall be fully liable for the performance of Services by such subcontractor and for compliance by such subcontractor with the terms of this Agreement, the relevant Statement or Work and
the Quality Agreement, (ii) the agreement between LONZA and such subcontractor must be consistent with LONZA’s obligations to CLIENT under this Agreement, the relevant Statement or Work and the Quality Agreement, and (iii) LONZA shall
be exclusively responsible for all costs associated with any such subcontract relationship. 

  
 30 

 17.12 Assignment. This Agreement shall be binding upon the
successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the
prior written consent of the other Party, except that a Party may make such an assignment or transfer to its Affiliate without the other Party’s consent, provided that such Party shall remain primarily liable for any acts or omissions of such
Affiliate. Any permitted assignment of this Agreement by either Party will be conditioned upon that Party’s permitted assignee agreeing in writing to comply with all the terms and conditions contained in this Agreement. Any purported assignment
without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. 

17.13 Waiver. The failure of any Party at any time or times to require performance of any provision of this
Agreement (including any Appendix hereto) will in no manner affect its rights at a later time to enforce the same. No waiver by any Party of any term, provision or condition contained in this Agreement (including any Appendix hereto), whether by
conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this Agreement (including any Appendix
hereto). 
 17.14 Dispute Resolution. Each of the Parties hereto agrees that any dispute or controversy
arising out of, relating to, or concerning any interpretation, construction, performance or breach of this Agreement, shall be settled by arbitration to be held in Singapore which shall be administered by the Singapore International Arbitration
Centre (“SIAC”) in accordance with the SIAC Arbitration Rules in force at the time of the commencement of the arbitration. There shall be three (3) arbitrators. The claimant shall select one (1) arbitrator, and the
respondent shall select one (1) arbitrator. The third arbitrator, who shall be the presiding arbitrator, shall be jointly appointed by the claimant and respondent. If either the claimant or the respondent fails to select the third arbitrator or
the Parties fail to agree on the choice of the third arbitrator, SIAC shall make the appointment on their behalf. The arbitration shall be conducted in English. The seat of arbitration shall be Singapore. The decision of the arbitration tribunal
shall be final, conclusive and binding on the Parties to the arbitration. 
 17.15 No Presumption Against
Drafter. For purposes of this Agreement, each Party hereby waives any rule of construction that requires that ambiguities in this Agreement (including any Appendix hereto) be construed against the drafter. 

17.16 Rights and Obligations of CLIENT. Gracell Suzhou and Gracell US shall each be individually
entitled to exercise all rights of CLIENT hereunder, and LONZA shall accordingly be entitled to rely on any notice duly received from either of Gracell Suzhou or Gracell US in accordance with section 17.3. Gracell Suzhou and Gracell US shall
be jointly and severally liable for all obligations of CLIENT hereunder. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 31 

 

 
 IN WITNESS WHEREOF, the Parties have
caused this Agreement to be executed as of March 31, 2021 by their duly authorized representatives. 
  

			
	GRACELL BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Wei Cao

 
			
	  
 Name: Wei Cao

 
 Title: CEO

 IN WITNESS WHEREOF, the
Parties have caused this Agreement to be executed as of March 31, 2021 by their duly authorized representatives. 
  

			
	SUZHOU GRACELL BIOTECHNOLOGIES, CO., LTD. (SEAL)
		
	By:	 	 /s/ Wei Cao

	
	Name: Wei Cao
	
	Title: CEO

 

 
 IN WITNESS WHEREOF, the Parties have caused this
Agreement to be executed as of March 31, 2021 by their duly authorized representatives. 
  

			
	LONZA HOUSTON, INC.
		
	By:	 	 /s/Thomas Fellner

	
	Name: Thomas Fellner
		
	Title:	 	VP, Global Head of Sales & Program Management

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]